id	sid	tid	token	lemma	pos
aiua-11052	1	1	stesura	stesura	PROPN
aiua-11052	1	2	seveso	seveso	PROPN
aiua-11052	1	3	archivio	archivio	PROPN
aiua-11052	1	4	italiano	italiano	X
aiua-11052	1	5	di	di	X
aiua-11052	1	6	urologia	urologia	PROPN
aiua-11052	1	7	e	e	PROPN
aiua-11052	1	8	andrologia	andrologia	NOUN
aiua-11052	1	9	2023	2023	NUM
aiua-11052	1	10	;	;	PUNCT
aiua-11052	1	11	95	95	NUM
aiua-11052	1	12	,	,	PUNCT
aiua-11052	1	13	1	1	NUM
aiua-11052	1	14	original	original	ADJ
aiua-11052	1	15	paper	paper	NOUN
aiua-11052	1	16	tion	tion	NOUN
aiua-11052	1	17	to	to	ADP
aiua-11052	1	18	castration	castration	NOUN
aiua-11052	1	19	resistance	resistance	NOUN
aiua-11052	1	20	,	,	PUNCT
aiua-11052	1	21	during	during	ADP
aiua-11052	1	22	which	which	PRON
aiua-11052	1	23	progression	progression	NOUN
aiua-11052	1	24	occurs	occur	VERB
aiua-11052	1	25	despite	despite	SCONJ
aiua-11052	1	26	continued	continue	VERB
aiua-11052	1	27	suppression	suppression	NOUN
aiua-11052	1	28	of	of	ADP
aiua-11052	1	29	testosterone	testosterone	NOUN
aiua-11052	1	30	.	.	PUNCT
aiua-11052	2	1	this	this	PRON
aiua-11052	2	2	is	be	AUX
aiua-11052	2	3	referred	refer	VERB
aiua-11052	2	4	to	to	ADP
aiua-11052	2	5	as	as	ADP
aiua-11052	2	6	metastatic	metastatic	ADJ
aiua-11052	2	7	castration	castration	NOUN
aiua-11052	2	8	-	-	PUNCT
aiua-11052	2	9	resistant	resistant	ADJ
aiua-11052	2	10	prostate	prostate	NOUN
aiua-11052	2	11	cancer	cancer	NOUN
aiua-11052	2	12	(	(	PUNCT
aiua-11052	2	13	mcrpc	mcrpc	NOUN
aiua-11052	2	14	)	)	PUNCT
aiua-11052	2	15	(	(	PUNCT
aiua-11052	2	16	2	2	NUM
aiua-11052	2	17	)	)	PUNCT
aiua-11052	2	18	.	.	PUNCT
aiua-11052	3	1	treatment	treatment	NOUN
aiua-11052	3	2	of	of	ADP
aiua-11052	3	3	mcrpc	mcrpc	NOUN
aiua-11052	3	4	has	have	AUX
aiua-11052	3	5	evolved	evolve	VERB
aiua-11052	3	6	over	over	ADP
aiua-11052	3	7	the	the	DET
aiua-11052	3	8	last	last	ADJ
aiua-11052	3	9	decade	decade	NOUN
aiua-11052	3	10	,	,	PUNCT
aiua-11052	3	11	with	with	ADP
aiua-11052	3	12	results	result	NOUN
aiua-11052	3	13	from	from	ADP
aiua-11052	3	14	large	large	ADJ
aiua-11052	3	15	randomized	randomized	ADJ
aiua-11052	3	16	clinical	clinical	ADJ
aiua-11052	3	17	trials	trial	NOUN
aiua-11052	3	18	leading	lead	VERB
aiua-11052	3	19	to	to	ADP
aiua-11052	3	20	the	the	DET
aiua-11052	3	21	approval	approval	NOUN
aiua-11052	3	22	of	of	ADP
aiua-11052	3	23	several	several	ADJ
aiua-11052	3	24	new	new	ADJ
aiua-11052	3	25	agents	agent	NOUN
aiua-11052	3	26	showing	show	VERB
aiua-11052	3	27	an	an	DET
aiua-11052	3	28	overall	overall	ADJ
aiua-11052	3	29	survival	survival	NOUN
aiua-11052	3	30	(	(	PUNCT
aiua-11052	3	31	os	os	NOUN
aiua-11052	3	32	)	)	PUNCT
aiua-11052	3	33	benefit	benefit	NOUN
aiua-11052	3	34	in	in	ADP
aiua-11052	3	35	patients	patient	NOUN
aiua-11052	3	36	with	with	ADP
aiua-11052	3	37	mcrpc	mcrpc	NOUN
aiua-11052	3	38	,	,	PUNCT
aiua-11052	3	39	both	both	PRON
aiua-11052	3	40	preand	preand	VERB
aiua-11052	3	41	post	post	ADJ
aiua-11052	3	42	-	-	ADJ
aiua-11052	3	43	chemotherapy	chemotherapy	NOUN
aiua-11052	3	44	-	-	PUNCT
aiua-11052	3	45	based	base	VERB
aiua-11052	3	46	regimens	regimen	NOUN
aiua-11052	3	47	(	(	PUNCT
aiua-11052	3	48	3	3	NUM
aiua-11052	3	49	,	,	PUNCT
aiua-11052	3	50	4	4	NUM
aiua-11052	3	51	)	)	PUNCT
aiua-11052	3	52	.	.	PUNCT
aiua-11052	4	1	abiraterone	abiraterone	NOUN
aiua-11052	4	2	acetate	acetate	NOUN
aiua-11052	4	3	(	(	PUNCT
aiua-11052	4	4	aa	aa	NOUN
aiua-11052	4	5	)	)	PUNCT
aiua-11052	4	6	is	be	AUX
aiua-11052	4	7	an	an	DET
aiua-11052	4	8	important	important	ADJ
aiua-11052	4	9	agent	agent	NOUN
aiua-11052	4	10	in	in	ADP
aiua-11052	4	11	the	the	DET
aiua-11052	4	12	treatment	treatment	NOUN
aiua-11052	4	13	of	of	ADP
aiua-11052	4	14	advanced	advanced	ADJ
aiua-11052	4	15	prostate	prostate	NOUN
aiua-11052	4	16	cancer	cancer	NOUN
aiua-11052	4	17	.	.	PUNCT
aiua-11052	5	1	it	it	PRON
aiua-11052	5	2	is	be	AUX
aiua-11052	5	3	a	a	DET
aiua-11052	5	4	selective	selective	ADJ
aiua-11052	5	5	inhibitor	inhibitor	NOUN
aiua-11052	5	6	of	of	ADP
aiua-11052	5	7	androgen	androgen	NOUN
aiua-11052	5	8	biosynthesis	biosynthesis	NOUN
aiua-11052	5	9	which	which	PRON
aiua-11052	5	10	potentially	potentially	ADV
aiua-11052	5	11	and	and	CCONJ
aiua-11052	5	12	irreversibly	irreversibly	ADV
aiua-11052	5	13	blocks	block	VERB
aiua-11052	5	14	cyp17	cyp17	NOUN
aiua-11052	5	15	,	,	PUNCT
aiua-11052	5	16	a	a	DET
aiua-11052	5	17	crucial	crucial	ADJ
aiua-11052	5	18	enzyme	enzyme	NOUN
aiua-11052	5	19	in	in	ADP
aiua-11052	5	20	estrogen	estrogen	NOUN
aiua-11052	5	21	and	and	CCONJ
aiua-11052	5	22	testosterone	testosterone	NOUN
aiua-11052	5	23	synthesis	synthesis	NOUN
aiua-11052	5	24	.	.	PUNCT
aiua-11052	6	1	it	it	PRON
aiua-11052	6	2	was	be	AUX
aiua-11052	6	3	primarily	primarily	ADV
aiua-11052	6	4	approved	approve	VERB
aiua-11052	6	5	for	for	ADP
aiua-11052	6	6	the	the	DET
aiua-11052	6	7	treatment	treatment	NOUN
aiua-11052	6	8	of	of	ADP
aiua-11052	6	9	metastatic	metastatic	ADJ
aiua-11052	6	10	castrate	castrate	NOUN
aiua-11052	6	11	-	-	PUNCT
aiua-11052	6	12	resistant	resistant	ADJ
aiua-11052	6	13	prostate	prostate	NOUN
aiua-11052	6	14	cancer	cancer	NOUN
aiua-11052	6	15	after	after	ADP
aiua-11052	6	16	failure	failure	NOUN
aiua-11052	6	17	of	of	ADP
aiua-11052	6	18	androgen	androgen	NOUN
aiua-11052	6	19	deprivation	deprivation	NOUN
aiua-11052	6	20	therapy	therapy	NOUN
aiua-11052	6	21	(	(	PUNCT
aiua-11052	6	22	5	5	NUM
aiua-11052	6	23	)	)	PUNCT
aiua-11052	6	24	.	.	PUNCT
aiua-11052	7	1	however	however	ADV
aiua-11052	7	2	,	,	PUNCT
aiua-11052	7	3	it	it	PRON
aiua-11052	7	4	is	be	AUX
aiua-11052	7	5	important	important	ADJ
aiua-11052	7	6	to	to	PART
aiua-11052	7	7	acknowledge	acknowledge	VERB
aiua-11052	7	8	that	that	SCONJ
aiua-11052	7	9	,	,	PUNCT
aiua-11052	7	10	although	although	SCONJ
aiua-11052	7	11	aa	aa	NOUN
aiua-11052	7	12	is	be	AUX
aiua-11052	7	13	effective	effective	ADJ
aiua-11052	7	14	in	in	ADP
aiua-11052	7	15	both	both	PRON
aiua-11052	7	16	preand	preand	NOUN
aiua-11052	7	17	post	post	ADJ
aiua-11052	7	18	-	-	ADJ
aiua-11052	7	19	chemotherapy	chemotherapy	ADJ
aiua-11052	7	20	setting	setting	NOUN
aiua-11052	7	21	,	,	PUNCT
aiua-11052	7	22	discrepancies	discrepancy	NOUN
aiua-11052	7	23	exist	exist	VERB
aiua-11052	7	24	regarding	regard	VERB
aiua-11052	7	25	its	its	PRON
aiua-11052	7	26	effectiveness	effectiveness	NOUN
aiua-11052	7	27	,	,	PUNCT
aiua-11052	7	28	with	with	ADP
aiua-11052	7	29	only	only	ADV
aiua-11052	7	30	a	a	DET
aiua-11052	7	31	fraction	fraction	NOUN
aiua-11052	7	32	of	of	ADP
aiua-11052	7	33	patients	patient	NOUN
aiua-11052	7	34	actually	actually	ADV
aiua-11052	7	35	benefiting	benefit	VERB
aiua-11052	7	36	in	in	ADP
aiua-11052	7	37	the	the	DET
aiua-11052	7	38	long	long	ADJ
aiua-11052	7	39	term	term	NOUN
aiua-11052	7	40	.	.	PUNCT
aiua-11052	8	1	prostate	prostate	NOUN
aiua-11052	8	2	-	-	PUNCT
aiua-11052	8	3	specific	specific	ADJ
aiua-11052	8	4	antigen	antigen	NOUN
aiua-11052	8	5	(	(	PUNCT
aiua-11052	8	6	psa	psa	NOUN
aiua-11052	8	7	)	)	PUNCT
aiua-11052	8	8	is	be	AUX
aiua-11052	8	9	widely	widely	ADV
aiua-11052	8	10	used	use	VERB
aiua-11052	8	11	to	to	PART
aiua-11052	8	12	monitor	monitor	VERB
aiua-11052	8	13	prostate	prostate	NOUN
aiua-11052	8	14	cancer	cancer	NOUN
aiua-11052	8	15	and	and	CCONJ
aiua-11052	8	16	its	its	PRON
aiua-11052	8	17	decline	decline	NOUN
aiua-11052	8	18	after	after	ADP
aiua-11052	8	19	chemotherapy	chemotherapy	NOUN
aiua-11052	8	20	has	have	AUX
aiua-11052	8	21	been	be	AUX
aiua-11052	8	22	acknowledged	acknowledge	VERB
aiua-11052	8	23	as	as	ADP
aiua-11052	8	24	a	a	DET
aiua-11052	8	25	valid	valid	ADJ
aiua-11052	8	26	surrogate	surrogate	NOUN
aiua-11052	8	27	for	for	ADP
aiua-11052	8	28	os	os	NOUN
aiua-11052	8	29	at	at	ADP
aiua-11052	8	30	3	3	NUM
aiua-11052	8	31	months	month	NOUN
aiua-11052	8	32	(	(	PUNCT
aiua-11052	8	33	6	6	NUM
aiua-11052	8	34	)	)	PUNCT
aiua-11052	8	35	.	.	PUNCT
aiua-11052	9	1	although	although	SCONJ
aiua-11052	9	2	,	,	PUNCT
aiua-11052	9	3	the	the	DET
aiua-11052	9	4	role	role	NOUN
aiua-11052	9	5	of	of	ADP
aiua-11052	9	6	psa	psa	NOUN
aiua-11052	9	7	response	response	NOUN
aiua-11052	9	8	after	after	ADP
aiua-11052	9	9	new	new	ADJ
aiua-11052	9	10	hormonal	hormonal	ADJ
aiua-11052	9	11	generation	generation	NOUN
aiua-11052	9	12	agents	agent	NOUN
aiua-11052	9	13	remains	remain	VERB
aiua-11052	9	14	uncertain	uncertain	ADJ
aiua-11052	9	15	(	(	PUNCT
aiua-11052	9	16	7	7	NUM
aiua-11052	9	17	,	,	PUNCT
aiua-11052	9	18	8)	8)	NUM
aiua-11052	9	19	.	.	PUNCT
aiua-11052	10	1	the	the	DET
aiua-11052	10	2	aim	aim	NOUN
aiua-11052	10	3	of	of	ADP
aiua-11052	10	4	this	this	DET
aiua-11052	10	5	study	study	NOUN
aiua-11052	10	6	is	be	AUX
aiua-11052	10	7	to	to	PART
aiua-11052	10	8	evaluate	evaluate	VERB
aiua-11052	10	9	the	the	DET
aiua-11052	10	10	efficacy	efficacy	NOUN
aiua-11052	10	11	and	and	CCONJ
aiua-11052	10	12	safety	safety	NOUN
aiua-11052	10	13	of	of	ADP
aiua-11052	10	14	aa	aa	NOUN
aiua-11052	10	15	in	in	ADP
aiua-11052	10	16	mcrpc	mcrpc	PROPN
aiua-11052	10	17	patients	patient	NOUN
aiua-11052	10	18	,	,	PUNCT
aiua-11052	10	19	regarding	regard	VERB
aiua-11052	10	20	early	early	ADJ
aiua-11052	10	21	psa	psa	NOUN
aiua-11052	10	22	response	response	NOUN
aiua-11052	10	23	as	as	ADP
aiua-11052	10	24	a	a	DET
aiua-11052	10	25	prognostic	prognostic	ADJ
aiua-11052	10	26	marker	marker	NOUN
aiua-11052	10	27	of	of	ADP
aiua-11052	10	28	os	os	NOUN
aiua-11052	10	29	.	.	PUNCT
aiua-11052	11	1	materials	material	NOUN
aiua-11052	11	2	and	and	CCONJ
aiua-11052	11	3	methods	method	NOUN
aiua-11052	11	4	patients	patient	NOUN
aiua-11052	11	5	with	with	ADP
aiua-11052	11	6	confirmed	confirm	VERB
aiua-11052	11	7	mcrpc	mcrpc	PROPN
aiua-11052	11	8	treated	treat	VERB
aiua-11052	11	9	with	with	ADP
aiua-11052	11	10	first	first	ADJ
aiua-11052	11	11	line	line	NOUN
aiua-11052	11	12	abiraterone	abiraterone	NOUN
aiua-11052	11	13	between	between	ADP
aiua-11052	11	14	2013	2013	NUM
aiua-11052	11	15	and	and	CCONJ
aiua-11052	11	16	2020	2020	NUM
aiua-11052	11	17	at	at	ADP
aiua-11052	11	18	hospital	hospital	NOUN
aiua-11052	11	19	garcia	garcia	PROPN
aiua-11052	11	20	de	de	ADP
aiua-11052	11	21	orta	orta	PROPN
aiua-11052	11	22	and	and	CCONJ
aiua-11052	11	23	centro	centro	PROPN
aiua-11052	11	24	hospitalar	hospitalar	PROPN
aiua-11052	11	25	barreiro	barreiro	PROPN
aiua-11052	11	26	montijo	montijo	PROPN
aiua-11052	11	27	were	be	AUX
aiua-11052	11	28	considered	consider	VERB
aiua-11052	11	29	for	for	ADP
aiua-11052	11	30	analysis	analysis	NOUN
aiua-11052	11	31	.	.	PUNCT
aiua-11052	12	1	psa	psa	NOUN
aiua-11052	12	2	value	value	NOUN
aiua-11052	12	3	at	at	ADP
aiua-11052	12	4	baseline	baseline	NOUN
aiua-11052	12	5	,	,	PUNCT
aiua-11052	12	6	at	at	ADP
aiua-11052	12	7	four	four	NUM
aiua-11052	12	8	,	,	PUNCT
aiua-11052	12	9	eight	eight	NUM
aiua-11052	12	10	,	,	PUNCT
aiua-11052	12	11	and	and	CCONJ
aiua-11052	12	12	twelve	twelve	NUM
aiua-11052	12	13	weeks	week	NOUN
aiua-11052	12	14	were	be	AUX
aiua-11052	12	15	required	require	VERB
aiua-11052	12	16	for	for	ADP
aiua-11052	12	17	study	study	NOUN
aiua-11052	12	18	inclusion	inclusion	NOUN
aiua-11052	12	19	.	.	PUNCT
aiua-11052	13	1	exclusion	exclusion	NOUN
aiua-11052	13	2	criteria	criterion	NOUN
aiua-11052	13	3	included	include	VERB
aiua-11052	13	4	absence	absence	NOUN
aiua-11052	13	5	of	of	ADP
aiua-11052	13	6	baseline	baseline	ADJ
aiua-11052	13	7	values	value	NOUN
aiua-11052	13	8	.	.	PUNCT
aiua-11052	14	1	demographics	demographic	NOUN
aiua-11052	14	2	and	and	CCONJ
aiua-11052	14	3	baseline	baseline	PROPN
aiua-11052	14	4	characteristics	characteristic	NOUN
aiua-11052	14	5	such	such	ADJ
aiua-11052	14	6	as	as	ADP
aiua-11052	14	7	prior	prior	ADJ
aiua-11052	14	8	docetaxel	docetaxel	NOUN
aiua-11052	14	9	exposure	exposure	NOUN
aiua-11052	14	10	were	be	AUX
aiua-11052	14	11	recorded	record	VERB
aiua-11052	14	12	,	,	PUNCT
aiua-11052	14	13	as	as	ADV
aiua-11052	14	14	well	well	ADV
aiua-11052	14	15	as	as	ADP
aiua-11052	14	16	routine	routine	ADJ
aiua-11052	14	17	lab	lab	NOUN
aiua-11052	14	18	studies	study	NOUN
aiua-11052	14	19	including	include	VERB
aiua-11052	14	20	psa	psa	NOUN
aiua-11052	14	21	,	,	PUNCT
aiua-11052	14	22	neutrophil	neutrophil	ADJ
aiua-11052	14	23	to	to	ADP
aiua-11052	14	24	lymphocyte	lymphocyte	ADJ
aiua-11052	14	25	ratio	ratio	NOUN
aiua-11052	14	26	(	(	PUNCT
aiua-11052	14	27	nl	nl	NOUN
aiua-11052	14	28	ratio	ratio	NOUN
aiua-11052	14	29	)	)	PUNCT
aiua-11052	14	30	,	,	PUNCT
aiua-11052	14	31	and	and	CCONJ
aiua-11052	14	32	hemoglobin	hemoglobin	NOUN
aiua-11052	14	33	(	(	PUNCT
aiua-11052	14	34	hgb	hgb	PROPN
aiua-11052	14	35	)	)	PUNCT
aiua-11052	14	36	at	at	ADP
aiua-11052	14	37	start	start	NOUN
aiua-11052	14	38	of	of	ADP
aiua-11052	14	39	treatment	treatment	NOUN
aiua-11052	14	40	,	,	PUNCT
aiua-11052	14	41	when	when	SCONJ
aiua-11052	14	42	available	available	ADJ
aiua-11052	14	43	(	(	PUNCT
aiua-11052	14	44	table	table	NOUN
aiua-11052	14	45	1	1	NUM
aiua-11052	14	46	)	)	PUNCT
aiua-11052	14	47	.	.	PUNCT
aiua-11052	15	1	the	the	DET
aiua-11052	15	2	primary	primary	ADJ
aiua-11052	15	3	investigation	investigation	NOUN
aiua-11052	15	4	of	of	ADP
aiua-11052	15	5	interest	interest	NOUN
aiua-11052	15	6	was	be	AUX
aiua-11052	15	7	psa	psa	NOUN
aiua-11052	15	8	decline	decline	NOUN
aiua-11052	15	9	as	as	ADP
aiua-11052	15	10	a	a	DET
aiua-11052	15	11	objectives	objective	NOUN
aiua-11052	15	12	:	:	PUNCT
aiua-11052	15	13	abiraterone	abiraterone	NOUN
aiua-11052	15	14	acetate	acetate	NOUN
aiua-11052	15	15	(	(	PUNCT
aiua-11052	15	16	aa	aa	NOUN
aiua-11052	15	17	)	)	PUNCT
aiua-11052	15	18	is	be	AUX
aiua-11052	15	19	an	an	DET
aiua-11052	15	20	important	important	ADJ
aiua-11052	15	21	agent	agent	NOUN
aiua-11052	15	22	in	in	ADP
aiua-11052	15	23	the	the	DET
aiua-11052	15	24	treatment	treatment	NOUN
aiua-11052	15	25	of	of	ADP
aiua-11052	15	26	advanced	advanced	ADJ
aiua-11052	15	27	prostate	prostate	NOUN
aiua-11052	15	28	cancer	cancer	NOUN
aiua-11052	15	29	.	.	PUNCT
aiua-11052	16	1	it	it	PRON
aiua-11052	16	2	was	be	AUX
aiua-11052	16	3	primarily	primarily	ADV
aiua-11052	16	4	approved	approve	VERB
aiua-11052	16	5	for	for	ADP
aiua-11052	16	6	the	the	DET
aiua-11052	16	7	treatment	treatment	NOUN
aiua-11052	16	8	of	of	ADP
aiua-11052	16	9	metastatic	metastatic	ADJ
aiua-11052	16	10	castration	castration	NOUN
aiua-11052	16	11	-	-	PUNCT
aiua-11052	16	12	resistant	resistant	ADJ
aiua-11052	16	13	prostate	prostate	NOUN
aiua-11052	16	14	cancer	cancer	NOUN
aiua-11052	16	15	(	(	PUNCT
aiua-11052	16	16	mcrpc	mcrpc	NOUN
aiua-11052	16	17	)	)	PUNCT
aiua-11052	16	18	after	after	ADP
aiua-11052	16	19	failure	failure	NOUN
aiua-11052	16	20	of	of	ADP
aiua-11052	16	21	androgen	androgen	NOUN
aiua-11052	16	22	deprivation	deprivation	NOUN
aiua-11052	16	23	therapy	therapy	NOUN
aiua-11052	16	24	.	.	PUNCT
aiua-11052	17	1	there	there	PRON
aiua-11052	17	2	is	be	VERB
aiua-11052	17	3	still	still	ADV
aiua-11052	17	4	no	no	DET
aiua-11052	17	5	available	available	ADJ
aiua-11052	17	6	strong	strong	ADJ
aiua-11052	17	7	data	datum	NOUN
aiua-11052	17	8	regarding	regard	VERB
aiua-11052	17	9	the	the	DET
aiua-11052	17	10	impact	impact	NOUN
aiua-11052	17	11	of	of	ADP
aiua-11052	17	12	early	early	ADJ
aiua-11052	17	13	decline	decline	NOUN
aiua-11052	17	14	of	of	ADP
aiua-11052	17	15	prostate	prostate	NOUN
aiua-11052	17	16	-	-	PUNCT
aiua-11052	17	17	specific	specific	ADJ
aiua-11052	17	18	antigen	antigen	NOUN
aiua-11052	17	19	(	(	PUNCT
aiua-11052	17	20	psa	psa	NOUN
aiua-11052	17	21	)	)	PUNCT
aiua-11052	17	22	in	in	ADP
aiua-11052	17	23	the	the	DET
aiua-11052	17	24	overall	overall	ADJ
aiua-11052	17	25	survival	survival	NOUN
aiua-11052	17	26	.	.	PUNCT
aiua-11052	18	1	the	the	DET
aiua-11052	18	2	aim	aim	NOUN
aiua-11052	18	3	of	of	ADP
aiua-11052	18	4	this	this	DET
aiua-11052	18	5	study	study	NOUN
aiua-11052	18	6	was	be	AUX
aiua-11052	18	7	to	to	PART
aiua-11052	18	8	evaluate	evaluate	VERB
aiua-11052	18	9	the	the	DET
aiua-11052	18	10	clinical	clinical	ADJ
aiua-11052	18	11	efficacy	efficacy	NOUN
aiua-11052	18	12	of	of	ADP
aiua-11052	18	13	an	an	DET
aiua-11052	18	14	early	early	ADJ
aiua-11052	18	15	prostate	prostate	NOUN
aiua-11052	18	16	-	-	PUNCT
aiua-11052	18	17	specific	specific	ADJ
aiua-11052	18	18	antigen	antigen	ADJ
aiua-11052	18	19	response	response	NOUN
aiua-11052	18	20	as	as	ADP
aiua-11052	18	21	a	a	DET
aiua-11052	18	22	predictor	predictor	NOUN
aiua-11052	18	23	of	of	ADP
aiua-11052	18	24	overall	overall	ADJ
aiua-11052	18	25	survival	survival	NOUN
aiua-11052	18	26	(	(	PUNCT
aiua-11052	18	27	os	os	NOUN
aiua-11052	18	28	)	)	PUNCT
aiua-11052	18	29	in	in	ADP
aiua-11052	18	30	metastatic	metastatic	ADJ
aiua-11052	18	31	castration	castration	NOUN
aiua-11052	18	32	-	-	PUNCT
aiua-11052	18	33	resistant	resistant	ADJ
aiua-11052	18	34	prostate	prostate	NOUN
aiua-11052	18	35	cancer	cancer	NOUN
aiua-11052	18	36	when	when	SCONJ
aiua-11052	18	37	treated	treat	VERB
aiua-11052	18	38	with	with	ADP
aiua-11052	18	39	abiraterone	abiraterone	NOUN
aiua-11052	18	40	acetate	acetate	NOUN
aiua-11052	18	41	.	.	PUNCT
aiua-11052	19	1	materials	material	NOUN
aiua-11052	19	2	and	and	CCONJ
aiua-11052	19	3	methods	method	NOUN
aiua-11052	19	4	:	:	PUNCT
aiua-11052	19	5	a	a	DET
aiua-11052	19	6	dual	dual	ADJ
aiua-11052	19	7	center	center	NOUN
aiua-11052	19	8	,	,	PUNCT
aiua-11052	19	9	retrospective	retrospective	ADJ
aiua-11052	19	10	,	,	PUNCT
aiua-11052	19	11	cohort	cohort	NOUN
aiua-11052	19	12	study	study	NOUN
aiua-11052	19	13	on	on	ADP
aiua-11052	19	14	patients	patient	NOUN
aiua-11052	19	15	diagnosed	diagnose	VERB
aiua-11052	19	16	with	with	ADP
aiua-11052	19	17	mcrpc	mcrpc	NOUN
aiua-11052	19	18	treated	treat	VERB
aiua-11052	19	19	with	with	ADP
aiua-11052	19	20	abiraterone	abiraterone	NOUN
aiua-11052	19	21	between	between	ADP
aiua-11052	19	22	2013	2013	NUM
aiua-11052	19	23	and	and	CCONJ
aiua-11052	19	24	2020	2020	NUM
aiua-11052	19	25	was	be	AUX
aiua-11052	19	26	performed	perform	VERB
aiua-11052	19	27	.	.	PUNCT
aiua-11052	20	1	primary	primary	ADJ
aiua-11052	20	2	endpoint	endpoint	NOUN
aiua-11052	20	3	was	be	AUX
aiua-11052	20	4	to	to	PART
aiua-11052	20	5	demonstrate	demonstrate	VERB
aiua-11052	20	6	the	the	DET
aiua-11052	20	7	efficacy	efficacy	NOUN
aiua-11052	20	8	of	of	ADP
aiua-11052	20	9	aa	aa	PROPN
aiua-11052	20	10	,	,	PUNCT
aiua-11052	20	11	with	with	ADP
aiua-11052	20	12	the	the	DET
aiua-11052	20	13	analysis	analysis	NOUN
aiua-11052	20	14	of	of	ADP
aiua-11052	20	15	psa	psa	NOUN
aiua-11052	20	16	decline	decline	NOUN
aiua-11052	20	17	,	,	PUNCT
aiua-11052	20	18	and	and	CCONJ
aiua-11052	20	19	the	the	DET
aiua-11052	20	20	correlation	correlation	NOUN
aiua-11052	20	21	with	with	ADP
aiua-11052	20	22	overall	overall	ADJ
aiua-11052	20	23	survival	survival	NOUN
aiua-11052	20	24	.	.	PUNCT
aiua-11052	21	1	results	result	NOUN
aiua-11052	21	2	:	:	PUNCT
aiua-11052	21	3	the	the	DET
aiua-11052	21	4	cohort	cohort	NOUN
aiua-11052	21	5	analysis	analysis	NOUN
aiua-11052	21	6	consisted	consist	VERB
aiua-11052	21	7	of	of	ADP
aiua-11052	21	8	84	84	NUM
aiua-11052	21	9	patients	patient	NOUN
aiua-11052	21	10	with	with	ADP
aiua-11052	21	11	a	a	DET
aiua-11052	21	12	median	median	ADJ
aiua-11052	21	13	age	age	NOUN
aiua-11052	21	14	of	of	ADP
aiua-11052	21	15	71	71	NUM
aiua-11052	21	16	±	±	NUM
aiua-11052	21	17	9	9	NUM
aiua-11052	21	18	years	year	NOUN
aiua-11052	21	19	.	.	PUNCT
aiua-11052	22	1	a	a	DET
aiua-11052	22	2	psa	psa	NOUN
aiua-11052	22	3	response	response	NOUN
aiua-11052	22	4	of	of	ADP
aiua-11052	22	5	>	>	X
aiua-11052	22	6	30	30	NUM
aiua-11052	22	7	%	%	NOUN
aiua-11052	22	8	and	and	CCONJ
aiua-11052	22	9	>	>	X
aiua-11052	22	10	50	50	NUM
aiua-11052	22	11	%	%	NOUN
aiua-11052	22	12	at	at	ADP
aiua-11052	22	13	60	60	NUM
aiua-11052	22	14	and	and	CCONJ
aiua-11052	22	15	90	90	NUM
aiua-11052	22	16	days	day	NOUN
aiua-11052	22	17	was	be	AUX
aiua-11052	22	18	associated	associate	VERB
aiua-11052	22	19	with	with	ADP
aiua-11052	22	20	improved	improved	ADJ
aiua-11052	22	21	os	os	NOUN
aiua-11052	22	22	.	.	PUNCT
aiua-11052	23	1	multivariate	multivariate	NOUN
aiua-11052	23	2	analysis	analysis	NOUN
aiua-11052	23	3	revealed	reveal	VERB
aiua-11052	23	4	that	that	SCONJ
aiua-11052	23	5	a	a	DET
aiua-11052	23	6	60	60	NUM
aiua-11052	23	7	day	day	NOUN
aiua-11052	23	8	psa	psa	NOUN
aiua-11052	23	9	decline	decline	NOUN
aiua-11052	23	10	of	of	ADP
aiua-11052	23	11	>	>	SYM
aiua-11052	23	12	30	30	NUM
aiua-11052	23	13	%	%	NOUN
aiua-11052	23	14	was	be	AUX
aiua-11052	23	15	predictive	predictive	ADJ
aiua-11052	23	16	of	of	ADP
aiua-11052	23	17	overall	overall	ADJ
aiua-11052	23	18	survival	survival	NOUN
aiua-11052	23	19	.	.	PUNCT
aiua-11052	24	1	median	median	PROPN
aiua-11052	24	2	os	os	NOUN
aiua-11052	24	3	of	of	ADP
aiua-11052	24	4	diagnosed	diagnose	VERB
aiua-11052	24	5	mcrpc	mcrpc	NOUN
aiua-11052	24	6	patients	patient	NOUN
aiua-11052	24	7	was	be	AUX
aiua-11052	24	8	28	28	NUM
aiua-11052	24	9	months	month	NOUN
aiua-11052	24	10	.	.	PUNCT
aiua-11052	25	1	docetaxel	docetaxel	PROPN
aiua-11052	25	2	pre	pre	NOUN
aiua-11052	25	3	-	-	NOUN
aiua-11052	25	4	treatment	treatment	NOUN
aiua-11052	25	5	was	be	AUX
aiua-11052	25	6	not	not	PART
aiua-11052	25	7	associated	associate	VERB
aiua-11052	25	8	with	with	ADP
aiua-11052	25	9	longer	long	ADJ
aiua-11052	25	10	os	os	NOUN
aiua-11052	25	11	.	.	PUNCT
aiua-11052	26	1	the	the	DET
aiua-11052	26	2	median	median	ADJ
aiua-11052	26	3	duration	duration	NOUN
aiua-11052	26	4	of	of	ADP
aiua-11052	26	5	drug	drug	NOUN
aiua-11052	26	6	exposure	exposure	NOUN
aiua-11052	26	7	for	for	ADP
aiua-11052	26	8	patients	patient	NOUN
aiua-11052	26	9	submitted	submit	VERB
aiua-11052	26	10	to	to	ADP
aiua-11052	26	11	aa	aa	PROPN
aiua-11052	26	12	was	be	AUX
aiua-11052	26	13	found	find	VERB
aiua-11052	26	14	to	to	PART
aiua-11052	26	15	be	be	AUX
aiua-11052	26	16	14	14	NUM
aiua-11052	26	17	months	month	NOUN
aiua-11052	26	18	.	.	PUNCT
aiua-11052	27	1	conclusions	conclusion	NOUN
aiua-11052	27	2	:	:	PUNCT
aiua-11052	27	3	early	early	ADJ
aiua-11052	27	4	psa	psa	NOUN
aiua-11052	27	5	response	response	NOUN
aiua-11052	27	6	rate	rate	NOUN
aiua-11052	27	7	can	can	AUX
aiua-11052	27	8	offer	offer	VERB
aiua-11052	27	9	clinically	clinically	ADV
aiua-11052	27	10	meaningful	meaningful	ADJ
aiua-11052	27	11	information	information	NOUN
aiua-11052	27	12	and	and	CCONJ
aiua-11052	27	13	can	can	AUX
aiua-11052	27	14	be	be	AUX
aiua-11052	27	15	considered	consider	VERB
aiua-11052	27	16	a	a	DET
aiua-11052	27	17	surrogate	surrogate	NOUN
aiua-11052	27	18	of	of	ADP
aiua-11052	27	19	longer	long	ADJ
aiua-11052	27	20	os	os	NOUN
aiua-11052	27	21	.	.	PUNCT
aiua-11052	28	1	a	a	DET
aiua-11052	28	2	>	>	SYM
aiua-11052	28	3	30	30	NUM
aiua-11052	28	4	%	%	NOUN
aiua-11052	28	5	or	or	CCONJ
aiua-11052	28	6	>	>	SYM
aiua-11052	28	7	50	50	NUM
aiua-11052	28	8	%	%	NOUN
aiua-11052	28	9	prostate	prostate	NOUN
aiua-11052	28	10	-	-	PUNCT
aiua-11052	28	11	specific	specific	ADJ
aiua-11052	28	12	antigen	antigen	NOUN
aiua-11052	28	13	decline	decline	NOUN
aiua-11052	28	14	at	at	ADP
aiua-11052	28	15	60	60	NUM
aiua-11052	28	16	and	and	CCONJ
aiua-11052	28	17	90	90	NUM
aiua-11052	28	18	days	day	NOUN
aiua-11052	28	19	provided	provide	VERB
aiua-11052	28	20	an	an	DET
aiua-11052	28	21	important	important	ADJ
aiua-11052	28	22	low	low	ADJ
aiua-11052	28	23	-	-	PUNCT
aiua-11052	28	24	cost	cost	NOUN
aiua-11052	28	25	clinical	clinical	ADJ
aiua-11052	28	26	tool	tool	NOUN
aiua-11052	28	27	to	to	PART
aiua-11052	28	28	predict	predict	VERB
aiua-11052	28	29	subsequent	subsequent	ADJ
aiua-11052	28	30	events	event	NOUN
aiua-11052	28	31	in	in	ADP
aiua-11052	28	32	mcrpc	mcrpc	NOUN
aiua-11052	28	33	patients	patient	NOUN
aiua-11052	28	34	treated	treat	VERB
aiua-11052	28	35	with	with	ADP
aiua-11052	28	36	abiraterone	abiraterone	NOUN
aiua-11052	28	37	.	.	PUNCT
aiua-11052	29	1	key	key	ADJ
aiua-11052	29	2	words	word	NOUN
aiua-11052	29	3	:	:	PUNCT
aiua-11052	29	4	abiraterone	abiraterone	NOUN
aiua-11052	29	5	;	;	PUNCT
aiua-11052	29	6	mcrpc	mcrpc	NOUN
aiua-11052	29	7	;	;	PUNCT
aiua-11052	29	8	psa	psa	VERB
aiua-11052	29	9	;	;	PUNCT
aiua-11052	29	10	overall	overall	ADJ
aiua-11052	29	11	survival	survival	NOUN
aiua-11052	29	12	;	;	PUNCT
aiua-11052	29	13	progression	progression	NOUN
aiua-11052	29	14	free	free	ADJ
aiua-11052	29	15	survival	survival	NOUN
aiua-11052	29	16	.	.	PUNCT
aiua-11052	29	17	submitted	submit	VERB
aiua-11052	29	18	2	2	NUM
aiua-11052	29	19	december	december	PROPN
aiua-11052	29	20	2022	2022	NUM
aiua-11052	29	21	;	;	PUNCT
aiua-11052	29	22	accepted	accept	VERB
aiua-11052	29	23	31	31	NUM
aiua-11052	29	24	december	december	PROPN
aiua-11052	29	25	2022	2022	NUM
aiua-11052	29	26	introduction	introduction	NOUN
aiua-11052	29	27	prostate	prostate	NOUN
aiua-11052	29	28	cancer	cancer	NOUN
aiua-11052	29	29	is	be	AUX
aiua-11052	29	30	the	the	DET
aiua-11052	29	31	second	second	ADJ
aiua-11052	29	32	most	most	ADV
aiua-11052	29	33	commonly	commonly	ADV
aiua-11052	29	34	diagnosed	diagnose	VERB
aiua-11052	29	35	malignancy	malignancy	NOUN
aiua-11052	29	36	in	in	ADP
aiua-11052	29	37	men	man	NOUN
aiua-11052	29	38	around	around	ADP
aiua-11052	29	39	the	the	DET
aiua-11052	29	40	world	world	NOUN
aiua-11052	29	41	with	with	ADP
aiua-11052	29	42	an	an	DET
aiua-11052	29	43	estimated	estimate	VERB
aiua-11052	29	44	1.111.700	1.111.700	NUM
aiua-11052	29	45	new	new	ADJ
aiua-11052	29	46	cases	case	NOUN
aiua-11052	29	47	and	and	CCONJ
aiua-11052	29	48	307.500	307.500	NUM
aiua-11052	29	49	deaths	death	NOUN
aiua-11052	29	50	per	per	ADP
aiua-11052	29	51	year	year	NOUN
aiua-11052	29	52	(	(	PUNCT
aiua-11052	29	53	1	1	NUM
aiua-11052	29	54	)	)	PUNCT
aiua-11052	29	55	.	.	PUNCT
aiua-11052	30	1	metastatic	metastatic	ADJ
aiua-11052	30	2	prostate	prostate	NOUN
aiua-11052	30	3	cancer	cancer	NOUN
aiua-11052	30	4	is	be	AUX
aiua-11052	30	5	characterized	characterize	VERB
aiua-11052	30	6	by	by	ADP
aiua-11052	30	7	a	a	DET
aiua-11052	30	8	period	period	NOUN
aiua-11052	30	9	during	during	ADP
aiua-11052	30	10	which	which	DET
aiua-11052	30	11	suppression	suppression	NOUN
aiua-11052	30	12	of	of	ADP
aiua-11052	30	13	serum	serum	NOUN
aiua-11052	30	14	testosterone	testosterone	NOUN
aiua-11052	30	15	with	with	ADP
aiua-11052	30	16	androgen	androgen	NOUN
aiua-11052	30	17	deprivation	deprivation	NOUN
aiua-11052	30	18	therapy	therapy	NOUN
aiua-11052	30	19	(	(	PUNCT
aiua-11052	30	20	adt	adt	NOUN
aiua-11052	30	21	)	)	PUNCT
aiua-11052	30	22	is	be	AUX
aiua-11052	30	23	sufficient	sufficient	ADJ
aiua-11052	30	24	to	to	PART
aiua-11052	30	25	control	control	VERB
aiua-11052	30	26	disease	disease	NOUN
aiua-11052	30	27	.	.	PUNCT
aiua-11052	31	1	unfortunately	unfortunately	ADV
aiua-11052	31	2	,	,	PUNCT
aiua-11052	31	3	this	this	DET
aiua-11052	31	4	period	period	NOUN
aiua-11052	31	5	is	be	AUX
aiua-11052	31	6	followed	follow	VERB
aiua-11052	31	7	by	by	ADP
aiua-11052	31	8	transiprostate	transiprostate	ADJ
aiua-11052	31	9	-	-	PUNCT
aiua-11052	31	10	specific	specific	ADJ
aiua-11052	31	11	antigen	antigen	ADJ
aiua-11052	31	12	response	response	NOUN
aiua-11052	31	13	after	after	ADP
aiua-11052	31	14	abiraterone	abiraterone	NOUN
aiua-11052	31	15	treatment	treatment	NOUN
aiua-11052	31	16	in	in	ADP
aiua-11052	31	17	mcrpc	mcrpc	NOUN
aiua-11052	31	18	:	:	PUNCT
aiua-11052	31	19	psa	psa	VERB
aiua-11052	31	20	as	as	ADP
aiua-11052	31	21	a	a	DET
aiua-11052	31	22	predictor	predictor	NOUN
aiua-11052	31	23	of	of	ADP
aiua-11052	31	24	overall	overall	ADJ
aiua-11052	31	25	survival	survival	PROPN
aiua-11052	31	26	alexandre	alexandre	PROPN
aiua-11052	31	27	mendonça	mendonça	PROPN
aiua-11052	31	28	macedo	macedo	PROPN
aiua-11052	31	29	1	1	NUM
aiua-11052	31	30	,	,	PUNCT
aiua-11052	31	31	rita	rita	PROPN
aiua-11052	31	32	gameiro	gameiro	PROPN
aiua-11052	31	33	marques	marques	PROPN
aiua-11052	31	34	2	2	PROPN
aiua-11052	31	35	,	,	PUNCT
aiua-11052	31	36	margarida	margarida	PROPN
aiua-11052	31	37	cunha	cunha	PROPN
aiua-11052	31	38	andré	andré	VERB
aiua-11052	31	39	1	1	NUM
aiua-11052	31	40	,	,	PUNCT
aiua-11052	31	41	nuno	nuno	PROPN
aiua-11052	31	42	silva	silva	PROPN
aiua-11052	31	43	figueira	figueira	PROPN
aiua-11052	31	44	1	1	NUM
aiua-11052	31	45	,	,	PUNCT
aiua-11052	31	46	miguel	miguel	PROPN
aiua-11052	31	47	leal	leal	PROPN
aiua-11052	31	48	carvalho	carvalho	PROPN
aiua-11052	31	49	1	1	NUM
aiua-11052	31	50	1	1	NUM
aiua-11052	31	51	urology	urology	NOUN
aiua-11052	31	52	department	department	NOUN
aiua-11052	31	53	,	,	PUNCT
aiua-11052	31	54	hospital	hospital	NOUN
aiua-11052	31	55	garcia	garcia	PROPN
aiua-11052	31	56	de	de	PROPN
aiua-11052	31	57	orta	orta	PROPN
aiua-11052	31	58	epe	epe	PROPN
aiua-11052	31	59	,	,	PUNCT
aiua-11052	31	60	almada	almada	PROPN
aiua-11052	31	61	,	,	PUNCT
aiua-11052	31	62	portugal	portugal	PROPN
aiua-11052	31	63	;	;	PUNCT
aiua-11052	31	64	2	2	NUM
aiua-11052	31	65	oncology	oncology	NOUN
aiua-11052	31	66	department	department	NOUN
aiua-11052	31	67	,	,	PUNCT
aiua-11052	31	68	centro	centro	PROPN
aiua-11052	31	69	hospitalar	hospitalar	PROPN
aiua-11052	31	70	barreiro	barreiro	PROPN
aiua-11052	31	71	montijo	montijo	PROPN
aiua-11052	31	72	,	,	PUNCT
aiua-11052	31	73	barreiro	barreiro	PROPN
aiua-11052	31	74	,	,	PUNCT
aiua-11052	31	75	portugal	portugal	PROPN
aiua-11052	31	76	.	.	PUNCT
aiua-11052	32	1	doi	doi	PROPN
aiua-11052	32	2	:	:	PUNCT
aiua-11052	32	3	10.4081	10.4081	NUM
aiua-11052	32	4	/	/	SYM
aiua-11052	32	5	aiua.2023.11052	aiua.2023.11052	PRON
aiua-11052	32	6	summary	summary	NOUN
aiua-11052	32	7	archivio	archivio	NOUN
aiua-11052	32	8	italiano	italiano	X
aiua-11052	32	9	di	di	X
aiua-11052	32	10	urologia	urologia	PROPN
aiua-11052	32	11	e	e	PROPN
aiua-11052	32	12	andrologia	andrologia	NOUN
aiua-11052	32	13	2023	2023	NUM
aiua-11052	32	14	;	;	PUNCT
aiua-11052	32	15	95	95	NUM
aiua-11052	32	16	,	,	PUNCT
aiua-11052	32	17	1	1	NUM
aiua-11052	32	18	a.	a.	NOUN
aiua-11052	32	19	mendonça	mendonça	PROPN
aiua-11052	32	20	macedo	macedo	PROPN
aiua-11052	32	21	,	,	PUNCT
aiua-11052	32	22	r.	r.	PROPN
aiua-11052	32	23	gameiro	gameiro	PROPN
aiua-11052	32	24	marques	marques	PROPN
aiua-11052	32	25	,	,	PUNCT
aiua-11052	32	26	m.	m.	PROPN
aiua-11052	32	27	cunha	cunha	NOUN
aiua-11052	32	28	andré	andré	PROPN
aiua-11052	32	29	,	,	PUNCT
aiua-11052	32	30	n.	n.	PROPN
aiua-11052	32	31	silva	silva	PROPN
aiua-11052	32	32	figueira	figueira	PROPN
aiua-11052	32	33	,	,	PUNCT
aiua-11052	32	34	m.	m.	NOUN
aiua-11052	32	35	leal	leal	PROPN
aiua-11052	32	36	carvalho	carvalho	PROPN
aiua-11052	32	37	predictor	predictor	NOUN
aiua-11052	32	38	of	of	ADP
aiua-11052	32	39	overall	overall	ADJ
aiua-11052	32	40	psa	psa	NOUN
aiua-11052	32	41	response	response	NOUN
aiua-11052	32	42	and	and	CCONJ
aiua-11052	32	43	survival	survival	NOUN
aiua-11052	32	44	.	.	PUNCT
aiua-11052	33	1	psa	psa	PROPN
aiua-11052	33	2	was	be	AUX
aiua-11052	33	3	procured	procure	VERB
aiua-11052	33	4	at	at	ADP
aiua-11052	33	5	four	four	NUM
aiua-11052	33	6	,	,	PUNCT
aiua-11052	33	7	eight	eight	NUM
aiua-11052	33	8	,	,	PUNCT
aiua-11052	33	9	and	and	CCONJ
aiua-11052	33	10	twelve	twelve	NUM
aiua-11052	33	11	weeks	week	NOUN
aiua-11052	33	12	.	.	PUNCT
aiua-11052	34	1	psa	psa	NOUN
aiua-11052	34	2	response	response	NOUN
aiua-11052	34	3	was	be	AUX
aiua-11052	34	4	defined	define	VERB
aiua-11052	34	5	as	as	ADP
aiua-11052	34	6	>	>	X
aiua-11052	34	7	30	30	NUM
aiua-11052	34	8	%	%	NOUN
aiua-11052	34	9	decrease	decrease	NOUN
aiua-11052	34	10	from	from	ADP
aiua-11052	34	11	the	the	DET
aiua-11052	34	12	psa	psa	NOUN
aiua-11052	34	13	at	at	ADP
aiua-11052	34	14	the	the	DET
aiua-11052	34	15	start	start	NOUN
aiua-11052	34	16	of	of	ADP
aiua-11052	34	17	treatment	treatment	NOUN
aiua-11052	34	18	.	.	PUNCT
aiua-11052	35	1	psa	psa	VERB
aiua-11052	35	2	responses	response	NOUN
aiua-11052	35	3	>	>	X
aiua-11052	35	4	50	50	NUM
aiua-11052	35	5	%	%	NOUN
aiua-11052	35	6	decrease	decrease	NOUN
aiua-11052	35	7	from	from	ADP
aiua-11052	35	8	the	the	DET
aiua-11052	35	9	psa	psa	NOUN
aiua-11052	35	10	at	at	ADP
aiua-11052	35	11	the	the	DET
aiua-11052	35	12	start	start	NOUN
aiua-11052	35	13	of	of	ADP
aiua-11052	35	14	treatment	treatment	NOUN
aiua-11052	35	15	were	be	AUX
aiua-11052	35	16	also	also	ADV
aiua-11052	35	17	analyzed	analyze	VERB
aiua-11052	35	18	.	.	PUNCT
aiua-11052	36	1	kaplan	kaplan	PROPN
aiua-11052	36	2	-	-	PUNCT
aiua-11052	36	3	meier	meier	PROPN
aiua-11052	36	4	analyses	analysis	NOUN
aiua-11052	36	5	were	be	AUX
aiua-11052	36	6	used	use	VERB
aiua-11052	36	7	to	to	PART
aiua-11052	36	8	estimate	estimate	VERB
aiua-11052	36	9	overall	overall	ADJ
aiua-11052	36	10	survival	survival	NOUN
aiua-11052	36	11	differences	difference	NOUN
aiua-11052	36	12	between	between	ADP
aiua-11052	36	13	groups	group	NOUN
aiua-11052	36	14	at	at	ADP
aiua-11052	36	15	each	each	DET
aiua-11052	36	16	time	time	NOUN
aiua-11052	36	17	point	point	NOUN
aiua-11052	36	18	.	.	PUNCT
aiua-11052	37	1	associations	association	NOUN
aiua-11052	37	2	between	between	ADP
aiua-11052	37	3	psa	psa	NOUN
aiua-11052	37	4	response	response	NOUN
aiua-11052	37	5	and	and	CCONJ
aiua-11052	37	6	survival	survival	NOUN
aiua-11052	37	7	were	be	AUX
aiua-11052	37	8	evaluated	evaluate	VERB
aiua-11052	37	9	via	via	ADP
aiua-11052	37	10	univariate	univariate	ADJ
aiua-11052	37	11	cox	cox	PROPN
aiua-11052	37	12	regression	regression	NOUN
aiua-11052	37	13	analysis	analysis	NOUN
aiua-11052	37	14	for	for	ADP
aiua-11052	37	15	≥	≥	NOUN
aiua-11052	37	16	30	30	NUM
aiua-11052	37	17	%	%	NOUN
aiua-11052	37	18	and	and	CCONJ
aiua-11052	37	19	≥	≥	NUM
aiua-11052	37	20	50	50	NUM
aiua-11052	37	21	%	%	NOUN
aiua-11052	37	22	response	response	NOUN
aiua-11052	37	23	at	at	ADP
aiua-11052	37	24	four	four	NUM
aiua-11052	37	25	,	,	PUNCT
aiua-11052	37	26	eight	eight	NUM
aiua-11052	37	27	,	,	PUNCT
aiua-11052	37	28	and	and	CCONJ
aiua-11052	37	29	twelve	twelve	NUM
aiua-11052	37	30	weeks	week	NOUN
aiua-11052	37	31	and	and	CCONJ
aiua-11052	37	32	with	with	ADP
aiua-11052	37	33	multivariate	multivariate	NOUN
aiua-11052	37	34	cox	cox	PROPN
aiua-11052	37	35	regression	regression	NOUN
aiua-11052	37	36	models	model	NOUN
aiua-11052	37	37	regarding	regard	VERB
aiua-11052	37	38	these	these	DET
aiua-11052	37	39	parameters	parameter	NOUN
aiua-11052	37	40	.	.	PUNCT
aiua-11052	38	1	data	datum	NOUN
aiua-11052	38	2	analysis	analysis	NOUN
aiua-11052	38	3	was	be	AUX
aiua-11052	38	4	completed	complete	VERB
aiua-11052	38	5	via	via	ADP
aiua-11052	38	6	ibm	ibm	PROPN
aiua-11052	38	7	spss	spss	PROPN
aiua-11052	38	8	software	software	NOUN
aiua-11052	38	9	.	.	PUNCT
aiua-11052	39	1	84	84	NUM
aiua-11052	39	2	male	male	ADJ
aiua-11052	39	3	patients	patient	NOUN
aiua-11052	39	4	diagnosed	diagnose	VERB
aiua-11052	39	5	with	with	ADP
aiua-11052	39	6	mcrpc	mcrpc	NOUN
aiua-11052	39	7	that	that	PRON
aiua-11052	39	8	experienced	experience	VERB
aiua-11052	39	9	treatment	treatment	NOUN
aiua-11052	39	10	failure	failure	NOUN
aiua-11052	39	11	with	with	ADP
aiua-11052	39	12	one	one	NUM
aiua-11052	39	13	or	or	CCONJ
aiua-11052	39	14	more	more	ADJ
aiua-11052	39	15	lines	line	NOUN
aiua-11052	39	16	of	of	ADP
aiua-11052	39	17	treatment	treatment	NOUN
aiua-11052	39	18	(	(	PUNCT
aiua-11052	39	19	hormonal	hormonal	ADJ
aiua-11052	39	20	manipulation	manipulation	NOUN
aiua-11052	39	21	or	or	CCONJ
aiua-11052	39	22	chemotherapy	chemotherapy	NOUN
aiua-11052	39	23	)	)	PUNCT
aiua-11052	39	24	were	be	AUX
aiua-11052	39	25	selected	select	VERB
aiua-11052	39	26	and	and	CCONJ
aiua-11052	39	27	abiraterone	abiraterone	NOUN
aiua-11052	39	28	acetate	acetate	NOUN
aiua-11052	39	29	(	(	PUNCT
aiua-11052	39	30	1.000	1.000	NUM
aiua-11052	39	31	mg	mg	NOUN
aiua-11052	39	32	daily	daily	ADV
aiua-11052	39	33	)	)	PUNCT
aiua-11052	39	34	along	along	ADP
aiua-11052	39	35	with	with	ADP
aiua-11052	39	36	prednisone	prednisone	PROPN
aiua-11052	39	37	(	(	PUNCT
aiua-11052	39	38	5	5	NUM
aiua-11052	39	39	mg	mg	NOUN
aiua-11052	39	40	twice	twice	ADV
aiua-11052	39	41	daily	daily	ADV
aiua-11052	39	42	)	)	PUNCT
aiua-11052	39	43	was	be	AUX
aiua-11052	39	44	administered	administer	VERB
aiua-11052	39	45	.	.	PUNCT
aiua-11052	40	1	results	result	NOUN
aiua-11052	40	2	in	in	ADP
aiua-11052	40	3	this	this	DET
aiua-11052	40	4	dual	dual	ADJ
aiua-11052	40	5	institution	institution	NOUN
aiua-11052	40	6	retrospective	retrospective	ADJ
aiua-11052	40	7	study	study	NOUN
aiua-11052	40	8	,	,	PUNCT
aiua-11052	40	9	a	a	DET
aiua-11052	40	10	total	total	NOUN
aiua-11052	40	11	of	of	ADP
aiua-11052	40	12	112	112	NUM
aiua-11052	40	13	mcrpc	mcrpc	NOUN
aiua-11052	40	14	patients	patient	NOUN
aiua-11052	40	15	were	be	AUX
aiua-11052	40	16	considered	consider	VERB
aiua-11052	40	17	.	.	PUNCT
aiua-11052	41	1	after	after	ADP
aiua-11052	41	2	strict	strict	ADJ
aiua-11052	41	3	analysis	analysis	NOUN
aiua-11052	41	4	,	,	PUNCT
aiua-11052	41	5	only	only	ADV
aiua-11052	41	6	84	84	NUM
aiua-11052	41	7	patients	patient	NOUN
aiua-11052	41	8	with	with	ADP
aiua-11052	41	9	a	a	DET
aiua-11052	41	10	median	median	ADJ
aiua-11052	41	11	age	age	NOUN
aiua-11052	41	12	of	of	ADP
aiua-11052	41	13	71	71	NUM
aiua-11052	41	14	±	±	NUM
aiua-11052	41	15	9	9	NUM
aiua-11052	41	16	years	year	NOUN
aiua-11052	41	17	were	be	AUX
aiua-11052	41	18	included	include	VERB
aiua-11052	41	19	for	for	ADP
aiua-11052	41	20	statistical	statistical	ADJ
aiua-11052	41	21	review	review	NOUN
aiua-11052	41	22	.	.	PUNCT
aiua-11052	42	1	67,9	67,9	NUM
aiua-11052	42	2	%	%	NOUN
aiua-11052	42	3	showed	show	VERB
aiua-11052	42	4	a	a	DET
aiua-11052	42	5	good	good	ADJ
aiua-11052	42	6	response	response	NOUN
aiua-11052	42	7	in	in	ADP
aiua-11052	42	8	psa	psa	NOUN
aiua-11052	42	9	reduction	reduction	NOUN
aiua-11052	42	10	.	.	PUNCT
aiua-11052	43	1	a	a	DET
aiua-11052	43	2	psa	psa	NOUN
aiua-11052	43	3	response	response	NOUN
aiua-11052	43	4	of	of	ADP
aiua-11052	43	5	>	>	X
aiua-11052	43	6	30	30	NUM
aiua-11052	43	7	%	%	NOUN
aiua-11052	43	8	and	and	CCONJ
aiua-11052	43	9	>	>	X
aiua-11052	43	10	50	50	NUM
aiua-11052	43	11	%	%	NOUN
aiua-11052	43	12	at	at	ADP
aiua-11052	43	13	60	60	NUM
aiua-11052	43	14	days	day	NOUN
aiua-11052	43	15	was	be	AUX
aiua-11052	43	16	associated	associate	VERB
aiua-11052	43	17	with	with	ADP
aiua-11052	43	18	improved	improve	VERB
aiua-11052	43	19	os	os	NOUN
aiua-11052	43	20	(	(	PUNCT
aiua-11052	43	21	log	log	VERB
aiua-11052	43	22	rank	rank	NOUN
aiua-11052	43	23	13.7	13.7	NUM
aiua-11052	43	24	,	,	PUNCT
aiua-11052	43	25	p	p	X
aiua-11052	43	26	<	<	X
aiua-11052	43	27	0.001	0.001	NUM
aiua-11052	43	28	,	,	PUNCT
aiua-11052	43	29	log	log	NOUN
aiua-11052	43	30	rank	rank	NOUN
aiua-11052	43	31	5,6	5,6	NUM
aiua-11052	43	32	,	,	PUNCT
aiua-11052	43	33	p	p	NOUN
aiua-11052	43	34	=	=	NOUN
aiua-11052	43	35	0.018	0.018	NUM
aiua-11052	43	36	)	)	PUNCT
aiua-11052	43	37	as	as	SCONJ
aiua-11052	43	38	compared	compare	VERB
aiua-11052	43	39	to	to	ADP
aiua-11052	43	40	subjects	subject	NOUN
aiua-11052	43	41	without	without	ADP
aiua-11052	43	42	such	such	DET
aiua-11052	43	43	a	a	DET
aiua-11052	43	44	decline	decline	NOUN
aiua-11052	43	45	(	(	PUNCT
aiua-11052	43	46	figure	figure	NOUN
aiua-11052	43	47	1	1	NUM
aiua-11052	43	48	and	and	CCONJ
aiua-11052	43	49	figure	figure	VERB
aiua-11052	43	50	2	2	NUM
aiua-11052	43	51	)	)	PUNCT
aiua-11052	43	52	.	.	PUNCT
aiua-11052	44	1	there	there	PRON
aiua-11052	44	2	was	be	VERB
aiua-11052	44	3	also	also	ADV
aiua-11052	44	4	a	a	DET
aiua-11052	44	5	strong	strong	ADJ
aiua-11052	44	6	correlation	correlation	NOUN
aiua-11052	44	7	of	of	ADP
aiua-11052	44	8	psa	psa	NOUN
aiua-11052	44	9	response	response	NOUN
aiua-11052	44	10	of	of	ADP
aiua-11052	44	11	>	>	X
aiua-11052	44	12	30	30	NUM
aiua-11052	44	13	%	%	NOUN
aiua-11052	44	14	and	and	CCONJ
aiua-11052	44	15	>	>	X
aiua-11052	44	16	50	50	NUM
aiua-11052	44	17	%	%	NOUN
aiua-11052	44	18	at	at	ADP
aiua-11052	44	19	90	90	NUM
aiua-11052	44	20	days	day	NOUN
aiua-11052	44	21	(	(	PUNCT
aiua-11052	44	22	log	log	NOUN
aiua-11052	44	23	rank	rank	NOUN
aiua-11052	44	24	6.7	6.7	NUM
aiua-11052	44	25	,	,	PUNCT
aiua-11052	44	26	p	p	X
aiua-11052	44	27	=	=	NOUN
aiua-11052	44	28	0.009	0.009	NUM
aiua-11052	44	29	and	and	CCONJ
aiua-11052	44	30	log	log	VERB
aiua-11052	44	31	rank	rank	NOUN
aiua-11052	44	32	3.7	3.7	NUM
aiua-11052	44	33	,	,	PUNCT
aiua-11052	44	34	p	p	X
aiua-11052	44	35	=	=	NOUN
aiua-11052	44	36	0.043	0.043	NUM
aiua-11052	44	37	)	)	PUNCT
aiua-11052	44	38	which	which	PRON
aiua-11052	44	39	was	be	AUX
aiua-11052	44	40	associated	associate	VERB
aiua-11052	44	41	with	with	ADP
aiua-11052	44	42	improved	improve	VERB
aiua-11052	44	43	os	os	NOUN
aiua-11052	44	44	(	(	PUNCT
aiua-11052	44	45	figure	figure	NOUN
aiua-11052	44	46	3	3	NUM
aiua-11052	44	47	and	and	CCONJ
aiua-11052	44	48	figure	figure	VERB
aiua-11052	44	49	4	4	NUM
aiua-11052	44	50	)	)	PUNCT
aiua-11052	44	51	.	.	PUNCT
aiua-11052	45	1	multivariate	multivariate	NOUN
aiua-11052	45	2	analysis	analysis	NOUN
aiua-11052	45	3	revealed	reveal	VERB
aiua-11052	45	4	that	that	SCONJ
aiua-11052	45	5	60	60	NUM
aiua-11052	45	6	-	-	PUNCT
aiua-11052	45	7	day	day	NOUN
aiua-11052	45	8	psa	psa	NOUN
aiua-11052	45	9	decline	decline	NOUN
aiua-11052	45	10	of	of	ADP
aiua-11052	45	11	>	>	SYM
aiua-11052	45	12	30	30	NUM
aiua-11052	45	13	%	%	NOUN
aiua-11052	45	14	was	be	AUX
aiua-11052	45	15	predictive	predictive	ADJ
aiua-11052	45	16	of	of	ADP
aiua-11052	45	17	overall	overall	ADJ
aiua-11052	45	18	survival	survival	NOUN
aiua-11052	45	19	(	(	PUNCT
aiua-11052	45	20	hr	hr	NOUN
aiua-11052	45	21	0.995	0.995	NUM
aiua-11052	45	22	,	,	PUNCT
aiua-11052	45	23	95	95	NUM
aiua-11052	45	24	%	%	NOUN
aiua-11052	45	25	ci	ci	NOUN
aiua-11052	45	26	0.13	0.13	NUM
aiua-11052	45	27	-	-	SYM
aiua-11052	45	28	0.57	0.57	NUM
aiua-11052	45	29	,	,	PUNCT
aiua-11052	45	30	p	p	NOUN
aiua-11052	45	31	=	=	NOUN
aiua-11052	45	32	0.001	0.001	NUM
aiua-11052	45	33	)	)	PUNCT
aiua-11052	45	34	.	.	PUNCT
aiua-11052	46	1	roc	roc	PROPN
aiua-11052	46	2	curve	curve	NOUN
aiua-11052	46	3	showed	show	VERB
aiua-11052	46	4	that	that	SCONJ
aiua-11052	46	5	psa	psa	NOUN
aiua-11052	46	6	value	value	NOUN
aiua-11052	46	7	at	at	ADP
aiua-11052	46	8	60	60	NUM
aiua-11052	46	9	days	day	NOUN
aiua-11052	46	10	is	be	AUX
aiua-11052	46	11	a	a	DET
aiua-11052	46	12	highly	highly	ADV
aiua-11052	46	13	specific	specific	ADJ
aiua-11052	46	14	tool	tool	NOUN
aiua-11052	46	15	to	to	PART
aiua-11052	46	16	determine	determine	VERB
aiua-11052	46	17	overall	overall	ADJ
aiua-11052	46	18	survival	survival	NOUN
aiua-11052	46	19	with	with	ADP
aiua-11052	46	20	a	a	DET
aiua-11052	46	21	cut	cut	VERB
aiua-11052	46	22	-	-	PUNCT
aiua-11052	46	23	off	off	ADP
aiua-11052	46	24	value	value	NOUN
aiua-11052	46	25	of	of	ADP
aiua-11052	46	26	>	>	SYM
aiua-11052	46	27	30	30	NUM
aiua-11052	46	28	%	%	NOUN
aiua-11052	46	29	(	(	PUNCT
aiua-11052	46	30	auc	auc	NOUN
aiua-11052	46	31	0.754	0.754	NUM
aiua-11052	46	32	,	,	PUNCT
aiua-11052	46	33	p	p	NOUN
aiua-11052	46	34	=	=	NOUN
aiua-11052	46	35	0.001	0.001	NUM
aiua-11052	46	36	)	)	PUNCT
aiua-11052	46	37	and	and	CCONJ
aiua-11052	46	38	it	it	PRON
aiua-11052	46	39	could	could	AUX
aiua-11052	46	40	be	be	AUX
aiua-11052	46	41	used	use	VERB
aiua-11052	46	42	as	as	ADP
aiua-11052	46	43	a	a	DET
aiua-11052	46	44	clinical	clinical	ADJ
aiua-11052	46	45	tool	tool	NOUN
aiua-11052	46	46	to	to	PART
aiua-11052	46	47	determine	determine	VERB
aiua-11052	46	48	patients	patient	NOUN
aiua-11052	46	49	that	that	SCONJ
aiua-11052	46	50	most	most	ADJ
aiua-11052	46	51	benefit	benefit	VERB
aiua-11052	46	52	from	from	ADP
aiua-11052	46	53	treatment	treatment	NOUN
aiua-11052	46	54	with	with	ADP
aiua-11052	46	55	abiraterone	abiraterone	NOUN
aiua-11052	46	56	(	(	PUNCT
aiua-11052	46	57	figure	figure	NOUN
aiua-11052	46	58	5	5	NUM
aiua-11052	46	59	)	)	PUNCT
aiua-11052	46	60	.	.	PUNCT
aiua-11052	47	1	median	median	PROPN
aiua-11052	47	2	os	os	NOUN
aiua-11052	47	3	of	of	ADP
aiua-11052	47	4	diagnosed	diagnose	VERB
aiua-11052	47	5	mcrpc	mcrpc	NOUN
aiua-11052	47	6	patients	patient	NOUN
aiua-11052	47	7	was	be	AUX
aiua-11052	47	8	28	28	NUM
aiua-11052	47	9	months	month	NOUN
aiua-11052	47	10	.	.	PUNCT
aiua-11052	48	1	docetaxel	docetaxel	PROPN
aiua-11052	48	2	pre	pre	NOUN
aiua-11052	48	3	-	-	NOUN
aiua-11052	48	4	treatment	treatment	NOUN
aiua-11052	48	5	in	in	ADP
aiua-11052	48	6	this	this	DET
aiua-11052	48	7	study	study	NOUN
aiua-11052	48	8	was	be	AUX
aiua-11052	48	9	not	not	PART
aiua-11052	48	10	associated	associate	VERB
aiua-11052	48	11	with	with	ADP
aiua-11052	48	12	longer	long	ADJ
aiua-11052	48	13	os	os	PROPN
aiua-11052	48	14	(	(	PUNCT
aiua-11052	48	15	log	log	PROPN
aiua-11052	48	16	rank	rank	NOUN
aiua-11052	48	17	:	:	PUNCT
aiua-11052	48	18	0.024	0.024	NUM
aiua-11052	48	19	,	,	PUNCT
aiua-11052	48	20	p	p	X
aiua-11052	48	21	=	=	NOUN
aiua-11052	48	22	0.878	0.878	NUM
aiua-11052	48	23	)	)	PUNCT
aiua-11052	48	24	(	(	PUNCT
aiua-11052	48	25	figure	figure	NOUN
aiua-11052	48	26	6	6	NUM
aiua-11052	48	27	)	)	PUNCT
aiua-11052	48	28	.	.	PUNCT
aiua-11052	49	1	table	table	NOUN
aiua-11052	49	2	1	1	NUM
aiua-11052	49	3	.	.	PUNCT
aiua-11052	50	1	psa	psa	NOUN
aiua-11052	50	2	decline	decline	VERB
aiua-11052	50	3	>	>	X
aiua-11052	50	4	50	50	NUM
aiua-11052	50	5	%	%	NOUN
aiua-11052	50	6	at	at	ADP
aiua-11052	50	7	60	60	NUM
aiua-11052	50	8	days	day	NOUN
aiua-11052	50	9	;	;	PUNCT
aiua-11052	50	10	log	log	VERB
aiua-11052	50	11	rank	rank	NOUN
aiua-11052	50	12	5.6	5.6	NUM
aiua-11052	50	13	,	,	PUNCT
aiua-11052	50	14	p	p	NOUN
aiua-11052	50	15	=	=	PROPN
aiua-11052	50	16	0.018	0.018	NUM
aiua-11052	50	17	.	.	PUNCT
aiua-11052	51	1	baseline	baseline	PROPN
aiua-11052	51	2	characteristics	characteristic	NOUN
aiua-11052	51	3	n	n	PRON
aiua-11052	51	4	median	median	ADJ
aiua-11052	51	5	total	total	ADJ
aiua-11052	51	6	patients	patient	NOUN
aiua-11052	51	7	84	84	NUM
aiua-11052	51	8	age	age	NOUN
aiua-11052	51	9	(	(	PUNCT
aiua-11052	51	10	years	year	NOUN
aiua-11052	51	11	)	)	PUNCT
aiua-11052	51	12	84	84	NUM
aiua-11052	51	13	71	71	NUM
aiua-11052	52	1	+	+	ADJ
aiua-11052	52	2	/9	/9	PROPN
aiua-11052	52	3	years	year	NOUN
aiua-11052	52	4	psa	psa	VERB
aiua-11052	52	5	at	at	ADP
aiua-11052	52	6	diagnosis	diagnosis	NOUN
aiua-11052	52	7	84	84	NUM
aiua-11052	52	8	57.73	57.73	NUM
aiua-11052	52	9	ng	ng	PROPN
aiua-11052	52	10	/	/	SYM
aiua-11052	52	11	dl	dl	PROPN
aiua-11052	53	1	[	[	X
aiua-11052	53	2	ir	ir	PROPN
aiua-11052	53	3	136	136	NUM
aiua-11052	53	4	]	]	PUNCT
aiua-11052	53	5	gleason	gleason	PROPN
aiua-11052	53	6	score	score	NOUN
aiua-11052	53	7	(	(	PUNCT
aiua-11052	53	8	median	median	PROPN
aiua-11052	53	9	)	)	PUNCT
aiua-11052	53	10	84	84	NUM
aiua-11052	53	11	7	7	NUM
aiua-11052	54	1	[	[	X
aiua-11052	54	2	ir	ir	PROPN
aiua-11052	54	3	2	2	NUM
aiua-11052	54	4	]	]	PUNCT
aiua-11052	54	5	neutrophil	neutrophil	ADJ
aiua-11052	54	6	/	/	SYM
aiua-11052	54	7	lymphocytes	lymphocytes	ADJ
aiua-11052	54	8	ratio	ratio	NOUN
aiua-11052	54	9	84	84	NUM
aiua-11052	54	10	2.3	2.3	NUM
aiua-11052	55	1	[	[	X
aiua-11052	55	2	ir	ir	NOUN
aiua-11052	55	3	1.28	1.28	NUM
aiua-11052	55	4	]	]	PUNCT
aiua-11052	55	5	patients	patient	NOUN
aiua-11052	55	6	without	without	ADP
aiua-11052	55	7	prior	prior	ADJ
aiua-11052	55	8	docetaxel	docetaxel	NOUN
aiua-11052	55	9	64	64	NUM
aiua-11052	55	10	patients	patient	NOUN
aiua-11052	55	11	with	with	ADP
aiua-11052	55	12	prior	prior	ADJ
aiua-11052	55	13	docetaxel	docetaxel	NOUN
aiua-11052	55	14	20	20	NUM
aiua-11052	55	15	abiraterone	abiraterone	NOUN
aiua-11052	55	16	duration	duration	NOUN
aiua-11052	55	17	(	(	PUNCT
aiua-11052	55	18	months	month	NOUN
aiua-11052	55	19	)	)	PUNCT
aiua-11052	55	20	84	84	NUM
aiua-11052	55	21	14	14	NUM
aiua-11052	55	22	time	time	NOUN
aiua-11052	55	23	until	until	ADP
aiua-11052	55	24	progression	progression	NOUN
aiua-11052	55	25	of	of	ADP
aiua-11052	55	26	disease	disease	NOUN
aiua-11052	55	27	with	with	ADP
aiua-11052	55	28	abiraterone	abiraterone	NOUN
aiua-11052	55	29	(	(	PUNCT
aiua-11052	55	30	months	month	NOUN
aiua-11052	55	31	)	)	PUNCT
aiua-11052	55	32	84	84	NUM
aiua-11052	55	33	12	12	NUM
aiua-11052	55	34	psa	psa	NOUN
aiua-11052	55	35	response	response	NOUN
aiua-11052	55	36	(	(	PUNCT
aiua-11052	55	37	%	%	INTJ
aiua-11052	55	38	)	)	PUNCT
aiua-11052	55	39	84	84	NUM
aiua-11052	55	40	67.9	67.9	NUM
aiua-11052	55	41	%	%	NOUN
aiua-11052	55	42	hematologic	hematologic	NOUN
aiua-11052	55	43	toxicity	toxicity	NOUN
aiua-11052	55	44	with	with	ADP
aiua-11052	55	45	abiraterone	abiraterone	NOUN
aiua-11052	55	46	2	2	NUM
aiua-11052	55	47	figure	figure	NOUN
aiua-11052	55	48	1	1	NUM
aiua-11052	55	49	.	.	PUNCT
aiua-11052	56	1	psa	psa	NOUN
aiua-11052	56	2	decline	decline	VERB
aiua-11052	56	3	>	>	X
aiua-11052	56	4	30	30	NUM
aiua-11052	56	5	%	%	NOUN
aiua-11052	56	6	at	at	ADP
aiua-11052	56	7	60	60	NUM
aiua-11052	56	8	days	day	NOUN
aiua-11052	56	9	log	log	VERB
aiua-11052	56	10	rank	rank	NOUN
aiua-11052	56	11	13.7	13.7	NUM
aiua-11052	56	12	,	,	PUNCT
aiua-11052	56	13	p	p	X
aiua-11052	56	14	<	<	X
aiua-11052	56	15	0.001	0.001	NUM
aiua-11052	56	16	.	.	PUNCT
aiua-11052	57	1	figure	figure	NOUN
aiua-11052	57	2	2	2	NUM
aiua-11052	57	3	.	.	PUNCT
aiua-11052	58	1	psa	psa	NOUN
aiua-11052	58	2	decline	decline	VERB
aiua-11052	58	3	>	>	X
aiua-11052	58	4	50	50	NUM
aiua-11052	58	5	%	%	NOUN
aiua-11052	58	6	at	at	ADP
aiua-11052	58	7	60	60	NUM
aiua-11052	58	8	days	day	NOUN
aiua-11052	58	9	.	.	PUNCT
aiua-11052	59	1	figure	figure	VERB
aiua-11052	59	2	3	3	NUM
aiua-11052	59	3	.	.	PUNCT
aiua-11052	59	4	psa	psa	NOUN
aiua-11052	59	5	decline	decline	VERB
aiua-11052	59	6	>	>	X
aiua-11052	59	7	30	30	NUM
aiua-11052	59	8	%	%	NOUN
aiua-11052	59	9	at	at	ADP
aiua-11052	59	10	90	90	NUM
aiua-11052	59	11	days	day	NOUN
aiua-11052	59	12	.	.	PUNCT
aiua-11052	60	1	log	log	VERB
aiua-11052	60	2	rank	rank	NOUN
aiua-11052	60	3	6.7	6.7	NUM
aiua-11052	60	4	p	p	NOUN
aiua-11052	60	5	=	=	NOUN
aiua-11052	60	6	0.009	0.009	NUM
aiua-11052	60	7	.	.	PUNCT
aiua-11052	60	8	figure	figure	NOUN
aiua-11052	60	9	4	4	NUM
aiua-11052	60	10	.	.	PUNCT
aiua-11052	61	1	psa	psa	NOUN
aiua-11052	61	2	decline	decline	VERB
aiua-11052	61	3	>	>	X
aiua-11052	61	4	50	50	NUM
aiua-11052	61	5	%	%	NOUN
aiua-11052	61	6	at	at	ADP
aiua-11052	61	7	90	90	NUM
aiua-11052	61	8	days	day	NOUN
aiua-11052	61	9	.	.	PUNCT
aiua-11052	62	1	log	log	AUX
aiua-11052	62	2	rank	rank	NOUN
aiua-11052	62	3	63.7	63.7	NUM
aiua-11052	62	4	p	p	NOUN
aiua-11052	62	5	=	=	NOUN
aiua-11052	62	6	0.043	0.043	NUM
aiua-11052	62	7	.	.	PUNCT
aiua-11052	63	1	archivio	archivio	NOUN
aiua-11052	63	2	italiano	italiano	X
aiua-11052	63	3	di	di	PROPN
aiua-11052	63	4	urologia	urologia	PROPN
aiua-11052	63	5	e	e	PROPN
aiua-11052	63	6	andrologia	andrologia	NOUN
aiua-11052	63	7	2023	2023	NUM
aiua-11052	63	8	;	;	PUNCT
aiua-11052	63	9	95	95	NUM
aiua-11052	63	10	,	,	PUNCT
aiua-11052	63	11	1	1	NUM
aiua-11052	63	12	psa	psa	VERB
aiua-11052	63	13	after	after	ADP
aiua-11052	63	14	abiraterone	abiraterone	NOUN
aiua-11052	63	15	the	the	DET
aiua-11052	63	16	median	median	ADJ
aiua-11052	63	17	duration	duration	NOUN
aiua-11052	63	18	of	of	ADP
aiua-11052	63	19	drug	drug	NOUN
aiua-11052	63	20	exposure	exposure	NOUN
aiua-11052	63	21	for	for	ADP
aiua-11052	63	22	crpc	crpc	ADV
aiua-11052	63	23	who	who	PRON
aiua-11052	63	24	received	receive	VERB
aiua-11052	63	25	aa	aa	NOUN
aiua-11052	63	26	was	be	AUX
aiua-11052	63	27	found	find	VERB
aiua-11052	63	28	to	to	PART
aiua-11052	63	29	be	be	AUX
aiua-11052	63	30	14	14	NUM
aiua-11052	64	1	[	[	X
aiua-11052	64	2	ir	ir	PROPN
aiua-11052	64	3	16	16	NUM
aiua-11052	64	4	]	]	SYM
aiua-11052	64	5	months	month	NOUN
aiua-11052	64	6	.	.	PUNCT
aiua-11052	65	1	regarding	regard	VERB
aiua-11052	65	2	adverse	adverse	ADJ
aiua-11052	65	3	events	event	NOUN
aiua-11052	65	4	,	,	PUNCT
aiua-11052	65	5	two	two	NUM
aiua-11052	65	6	patients	patient	NOUN
aiua-11052	65	7	revealed	reveal	VERB
aiua-11052	65	8	hematologic	hematologic	ADJ
aiua-11052	65	9	toxicity	toxicity	NOUN
aiua-11052	65	10	,	,	PUNCT
aiua-11052	65	11	which	which	PRON
aiua-11052	65	12	did	do	AUX
aiua-11052	65	13	n’t	not	PART
aiua-11052	65	14	lead	lead	VERB
aiua-11052	65	15	to	to	ADP
aiua-11052	65	16	treatment	treatment	NOUN
aiua-11052	65	17	discontinuation	discontinuation	NOUN
aiua-11052	65	18	.	.	PUNCT
aiua-11052	66	1	discussion	discussion	NOUN
aiua-11052	66	2	there	there	PRON
aiua-11052	66	3	is	be	VERB
aiua-11052	66	4	a	a	DET
aiua-11052	66	5	growing	grow	VERB
aiua-11052	66	6	number	number	NOUN
aiua-11052	66	7	of	of	ADP
aiua-11052	66	8	therapeutic	therapeutic	ADJ
aiua-11052	66	9	options	option	NOUN
aiua-11052	66	10	capable	capable	ADJ
aiua-11052	66	11	of	of	ADP
aiua-11052	66	12	extending	extend	VERB
aiua-11052	66	13	survival	survival	NOUN
aiua-11052	66	14	in	in	ADP
aiua-11052	66	15	mcrpc	mcrpc	NOUN
aiua-11052	66	16	patients	patient	NOUN
aiua-11052	66	17	.	.	PUNCT
aiua-11052	67	1	despite	despite	SCONJ
aiua-11052	67	2	that	that	PRON
aiua-11052	67	3	,	,	PUNCT
aiua-11052	67	4	there	there	PRON
aiua-11052	67	5	is	be	VERB
aiua-11052	67	6	a	a	DET
aiua-11052	67	7	lack	lack	NOUN
aiua-11052	67	8	for	for	ADP
aiua-11052	67	9	biomarkers	biomarker	NOUN
aiua-11052	67	10	that	that	PRON
aiua-11052	67	11	can	can	AUX
aiua-11052	67	12	simultaneously	simultaneously	ADV
aiua-11052	67	13	guide	guide	VERB
aiua-11052	67	14	treatment	treatment	NOUN
aiua-11052	67	15	decisions	decision	NOUN
aiua-11052	67	16	and	and	CCONJ
aiua-11052	67	17	predict	predict	VERB
aiua-11052	67	18	which	which	DET
aiua-11052	67	19	patients	patient	NOUN
aiua-11052	67	20	will	will	AUX
aiua-11052	67	21	benefit	benefit	VERB
aiua-11052	67	22	the	the	DET
aiua-11052	67	23	most	most	ADJ
aiua-11052	67	24	from	from	ADP
aiua-11052	67	25	these	these	DET
aiua-11052	67	26	treatments	treatment	NOUN
aiua-11052	67	27	.	.	PUNCT
aiua-11052	68	1	aa	aa	NOUN
aiua-11052	68	2	and	and	CCONJ
aiua-11052	68	3	enzalutamide	enzalutamide	ADV
aiua-11052	68	4	have	have	AUX
aiua-11052	68	5	shown	show	VERB
aiua-11052	68	6	clinical	clinical	ADJ
aiua-11052	68	7	efficacy	efficacy	NOUN
aiua-11052	68	8	in	in	ADP
aiua-11052	68	9	multicenter	multicenter	ADJ
aiua-11052	68	10	phase	phase	NOUN
aiua-11052	68	11	iii	iii	NUM
aiua-11052	68	12	rct	rct	PROPN
aiua-11052	68	13	’s	’s	PART
aiua-11052	68	14	(	(	PUNCT
aiua-11052	68	15	9	9	NUM
aiua-11052	68	16	)	)	PUNCT
aiua-11052	68	17	,	,	PUNCT
aiua-11052	68	18	although	although	SCONJ
aiua-11052	68	19	evidence	evidence	NOUN
aiua-11052	68	20	is	be	AUX
aiua-11052	68	21	not	not	PART
aiua-11052	68	22	clear	clear	ADJ
aiua-11052	68	23	regarding	regard	VERB
aiua-11052	68	24	which	which	DET
aiua-11052	68	25	drug	drug	NOUN
aiua-11052	68	26	results	result	VERB
aiua-11052	68	27	in	in	ADP
aiua-11052	68	28	a	a	DET
aiua-11052	68	29	better	well	ADV
aiua-11052	68	30	clinical	clinical	ADJ
aiua-11052	68	31	and	and	CCONJ
aiua-11052	68	32	biochemical	biochemical	ADJ
aiua-11052	68	33	response	response	NOUN
aiua-11052	68	34	.	.	PUNCT
aiua-11052	69	1	some	some	DET
aiua-11052	69	2	evidence	evidence	NOUN
aiua-11052	69	3	suggests	suggest	VERB
aiua-11052	69	4	there	there	PRON
aiua-11052	69	5	is	be	VERB
aiua-11052	69	6	a	a	DET
aiua-11052	69	7	better	well	ADJ
aiua-11052	69	8	biochemical	biochemical	ADJ
aiua-11052	69	9	response	response	NOUN
aiua-11052	69	10	in	in	ADP
aiua-11052	69	11	favor	favor	NOUN
aiua-11052	69	12	of	of	ADP
aiua-11052	69	13	enzalutamide	enzalutamide	NOUN
aiua-11052	69	14	versus	versus	ADP
aiua-11052	69	15	abiraterone	abiraterone	NOUN
aiua-11052	69	16	,	,	PUNCT
aiua-11052	69	17	particularly	particularly	ADV
aiua-11052	69	18	in	in	ADP
aiua-11052	69	19	those	those	DET
aiua-11052	69	20	patients	patient	NOUN
aiua-11052	69	21	submitted	submit	VERB
aiua-11052	69	22	to	to	ADP
aiua-11052	69	23	previous	previous	ADJ
aiua-11052	69	24	taxane	taxane	NOUN
aiua-11052	69	25	therapy	therapy	NOUN
aiua-11052	69	26	(	(	PUNCT
aiua-11052	69	27	10	10	NUM
aiua-11052	69	28	)	)	PUNCT
aiua-11052	69	29	.	.	PUNCT
aiua-11052	70	1	however	however	ADV
aiua-11052	70	2	,	,	PUNCT
aiua-11052	70	3	in	in	ADP
aiua-11052	70	4	patients	patient	NOUN
aiua-11052	70	5	achieving	achieve	VERB
aiua-11052	70	6	biochemical	biochemical	ADJ
aiua-11052	70	7	response	response	NOUN
aiua-11052	70	8	,	,	PUNCT
aiua-11052	70	9	this	this	DET
aiua-11052	70	10	advantage	advantage	NOUN
aiua-11052	70	11	is	be	AUX
aiua-11052	70	12	not	not	PART
aiua-11052	70	13	consistent	consistent	ADJ
aiua-11052	70	14	what	what	PRON
aiua-11052	70	15	suggests	suggest	VERB
aiua-11052	70	16	that	that	SCONJ
aiua-11052	70	17	there	there	PRON
aiua-11052	70	18	is	be	VERB
aiua-11052	70	19	a	a	DET
aiua-11052	70	20	need	need	NOUN
aiua-11052	70	21	for	for	ADP
aiua-11052	70	22	prognostic	prognostic	ADJ
aiua-11052	70	23	biochemical	biochemical	ADJ
aiua-11052	70	24	markers	marker	NOUN
aiua-11052	70	25	to	to	PART
aiua-11052	70	26	predict	predict	VERB
aiua-11052	70	27	which	which	DET
aiua-11052	70	28	patients	patient	NOUN
aiua-11052	70	29	will	will	AUX
aiua-11052	70	30	benefit	benefit	VERB
aiua-11052	70	31	the	the	DET
aiua-11052	70	32	most	most	ADJ
aiua-11052	70	33	from	from	ADP
aiua-11052	70	34	each	each	DET
aiua-11052	70	35	novel	novel	ADJ
aiua-11052	70	36	hormonal	hormonal	ADJ
aiua-11052	70	37	agent	agent	NOUN
aiua-11052	70	38	.	.	PUNCT
aiua-11052	71	1	thus	thus	ADV
aiua-11052	71	2	,	,	PUNCT
aiua-11052	71	3	the	the	DET
aiua-11052	71	4	development	development	NOUN
aiua-11052	71	5	of	of	ADP
aiua-11052	71	6	new	new	ADJ
aiua-11052	71	7	surrogate	surrogate	ADJ
aiua-11052	71	8	markers	marker	NOUN
aiua-11052	71	9	for	for	ADP
aiua-11052	71	10	clinical	clinical	ADJ
aiua-11052	71	11	outcomes	outcome	NOUN
aiua-11052	71	12	is	be	AUX
aiua-11052	71	13	becoming	become	VERB
aiua-11052	71	14	increasingly	increasingly	ADV
aiua-11052	71	15	important	important	ADJ
aiua-11052	71	16	with	with	ADP
aiua-11052	71	17	the	the	DET
aiua-11052	71	18	emergence	emergence	NOUN
aiua-11052	71	19	of	of	ADP
aiua-11052	71	20	multiple	multiple	ADJ
aiua-11052	71	21	lines	line	NOUN
aiua-11052	71	22	of	of	ADP
aiua-11052	71	23	treatment	treatment	NOUN
aiua-11052	71	24	with	with	ADP
aiua-11052	71	25	better	well	ADJ
aiua-11052	71	26	survival	survival	NOUN
aiua-11052	71	27	benefit	benefit	NOUN
aiua-11052	71	28	for	for	ADP
aiua-11052	71	29	mcrpc	mcrpc	NOUN
aiua-11052	71	30	patients	patient	NOUN
aiua-11052	71	31	.	.	PUNCT
aiua-11052	72	1	psa	psa	VERB
aiua-11052	72	2	remains	remain	VERB
aiua-11052	72	3	a	a	DET
aiua-11052	72	4	questionable	questionable	ADJ
aiua-11052	72	5	surrogate	surrogate	NOUN
aiua-11052	72	6	for	for	ADP
aiua-11052	72	7	survival	survival	NOUN
aiua-11052	72	8	in	in	ADP
aiua-11052	72	9	latestage	latestage	NOUN
aiua-11052	72	10	prostate	prostate	NOUN
aiua-11052	72	11	cancer	cancer	NOUN
aiua-11052	72	12	.	.	PUNCT
aiua-11052	73	1	prostate	prostate	NOUN
aiua-11052	73	2	cancer	cancer	NOUN
aiua-11052	73	3	clinical	clinical	ADJ
aiua-11052	73	4	trials	trial	NOUN
aiua-11052	73	5	working	working	NOUN
aiua-11052	73	6	group	group	NOUN
aiua-11052	73	7	(	(	PUNCT
aiua-11052	73	8	pcwg	pcwg	VERB
aiua-11052	73	9	)	)	PUNCT
aiua-11052	73	10	2	2	NUM
aiua-11052	73	11	states	state	VERB
aiua-11052	73	12	that	that	SCONJ
aiua-11052	73	13	the	the	DET
aiua-11052	73	14	clinical	clinical	ADJ
aiua-11052	73	15	significance	significance	NOUN
aiua-11052	73	16	of	of	ADP
aiua-11052	73	17	a	a	DET
aiua-11052	73	18	post	post	ADJ
aiua-11052	73	19	-	-	NOUN
aiua-11052	73	20	therapy	therapy	ADJ
aiua-11052	73	21	psa	psa	NOUN
aiua-11052	73	22	decline	decline	NOUN
aiua-11052	73	23	remains	remain	VERB
aiua-11052	73	24	controversial	controversial	ADJ
aiua-11052	73	25	and	and	CCONJ
aiua-11052	73	26	advises	advise	VERB
aiua-11052	73	27	against	against	ADP
aiua-11052	73	28	its	its	PRON
aiua-11052	73	29	early	early	ADJ
aiua-11052	73	30	use	use	NOUN
aiua-11052	73	31	.	.	PUNCT
aiua-11052	74	1	in	in	ADP
aiua-11052	74	2	fact	fact	NOUN
aiua-11052	74	3	,	,	PUNCT
aiua-11052	74	4	an	an	DET
aiua-11052	74	5	increase	increase	NOUN
aiua-11052	74	6	in	in	ADP
aiua-11052	74	7	serum	serum	NOUN
aiua-11052	74	8	psa	psa	NOUN
aiua-11052	74	9	,	,	PUNCT
aiua-11052	74	10	or	or	CCONJ
aiua-11052	74	11	‘	'	PUNCT
aiua-11052	74	12	flare	flare	NOUN
aiua-11052	74	13	’	'	PUNCT
aiua-11052	74	14	,	,	PUNCT
aiua-11052	74	15	may	may	AUX
aiua-11052	74	16	occur	occur	VERB
aiua-11052	74	17	in	in	ADP
aiua-11052	74	18	some	some	DET
aiua-11052	74	19	patients	patient	NOUN
aiua-11052	74	20	before	before	SCONJ
aiua-11052	74	21	they	they	PRON
aiua-11052	74	22	experience	experience	VERB
aiua-11052	74	23	a	a	DET
aiua-11052	74	24	subsequent	subsequent	ADJ
aiua-11052	74	25	and	and	CCONJ
aiua-11052	74	26	sometimes	sometimes	ADV
aiua-11052	74	27	significant	significant	ADJ
aiua-11052	74	28	psa	psa	NOUN
aiua-11052	74	29	decline	decline	NOUN
aiua-11052	74	30	.	.	PUNCT
aiua-11052	75	1	this	this	PRON
aiua-11052	75	2	is	be	AUX
aiua-11052	75	3	why	why	SCONJ
aiua-11052	75	4	pcwg2	pcwg2	NOUN
aiua-11052	75	5	recommends	recommend	VERB
aiua-11052	75	6	securing	secure	VERB
aiua-11052	75	7	a	a	DET
aiua-11052	75	8	sufficiently	sufficiently	ADV
aiua-11052	75	9	large	large	ADJ
aiua-11052	75	10	drug	drug	NOUN
aiua-11052	75	11	exposure	exposure	NOUN
aiua-11052	75	12	window	window	NOUN
aiua-11052	75	13	and	and	CCONJ
aiua-11052	75	14	avoid	avoid	VERB
aiua-11052	75	15	relying	rely	VERB
aiua-11052	75	16	on	on	ADP
aiua-11052	75	17	serum	serum	NOUN
aiua-11052	75	18	psa	psa	NOUN
aiua-11052	75	19	decline	decline	NOUN
aiua-11052	75	20	as	as	ADP
aiua-11052	75	21	a	a	DET
aiua-11052	75	22	surrogate	surrogate	NOUN
aiua-11052	75	23	for	for	ADP
aiua-11052	75	24	clinical	clinical	ADJ
aiua-11052	75	25	benefit	benefit	NOUN
aiua-11052	75	26	.	.	PUNCT
aiua-11052	76	1	perhaps	perhaps	ADV
aiua-11052	76	2	even	even	ADV
aiua-11052	76	3	more	more	ADV
aiua-11052	76	4	importantly	importantly	ADV
aiua-11052	76	5	,	,	PUNCT
aiua-11052	76	6	the	the	DET
aiua-11052	76	7	group	group	NOUN
aiua-11052	76	8	advises	advise	VERB
aiua-11052	76	9	not	not	PART
aiua-11052	76	10	to	to	PART
aiua-11052	76	11	interpret	interpret	VERB
aiua-11052	76	12	a	a	DET
aiua-11052	76	13	rise	rise	NOUN
aiua-11052	76	14	in	in	ADP
aiua-11052	76	15	serum	serum	NOUN
aiua-11052	76	16	psa	psa	NOUN
aiua-11052	76	17	as	as	ADP
aiua-11052	76	18	progression	progression	NOUN
aiua-11052	76	19	and	and	CCONJ
aiua-11052	76	20	early	early	ADV
aiua-11052	76	21	withdrawing	withdraw	VERB
aiua-11052	76	22	a	a	DET
aiua-11052	76	23	therapy	therapy	NOUN
aiua-11052	76	24	from	from	ADP
aiua-11052	76	25	which	which	PRON
aiua-11052	76	26	the	the	DET
aiua-11052	76	27	patient	patient	NOUN
aiua-11052	76	28	may	may	AUX
aiua-11052	76	29	benefit	benefit	VERB
aiua-11052	76	30	(	(	PUNCT
aiua-11052	76	31	11	11	NUM
aiua-11052	76	32	)	)	PUNCT
aiua-11052	76	33	.	.	PUNCT
aiua-11052	77	1	nonetheless	nonetheless	ADV
aiua-11052	77	2	,	,	PUNCT
aiua-11052	77	3	drugs	drug	NOUN
aiua-11052	77	4	targeting	target	VERB
aiua-11052	77	5	androgen	androgen	NOUN
aiua-11052	77	6	receptor	receptor	NOUN
aiua-11052	77	7	(	(	PUNCT
aiua-11052	77	8	ar	ar	NOUN
aiua-11052	77	9	)	)	PUNCT
aiua-11052	77	10	signaling	signal	VERB
aiua-11052	77	11	,	,	PUNCT
aiua-11052	77	12	such	such	ADJ
aiua-11052	77	13	as	as	ADP
aiua-11052	77	14	aa	aa	NOUN
aiua-11052	77	15	,	,	PUNCT
aiua-11052	77	16	may	may	AUX
aiua-11052	77	17	have	have	VERB
aiua-11052	77	18	a	a	DET
aiua-11052	77	19	different	different	ADJ
aiua-11052	77	20	association	association	NOUN
aiua-11052	77	21	to	to	ADP
aiua-11052	77	22	an	an	DET
aiua-11052	77	23	early	early	ADJ
aiua-11052	77	24	psa	psa	NOUN
aiua-11052	77	25	decrease	decrease	NOUN
aiua-11052	77	26	,	,	PUNCT
aiua-11052	77	27	since	since	SCONJ
aiua-11052	77	28	psa	psa	NOUN
aiua-11052	77	29	is	be	AUX
aiua-11052	77	30	a	a	DET
aiua-11052	77	31	pharmacodynamic	pharmacodynamic	ADJ
aiua-11052	77	32	biomarker	biomarker	NOUN
aiua-11052	77	33	of	of	ADP
aiua-11052	77	34	androgen	androgen	NOUN
aiua-11052	77	35	receptor	receptor	NOUN
aiua-11052	77	36	signaling	signal	VERB
aiua-11052	77	37	in	in	ADP
aiua-11052	77	38	absence	absence	NOUN
aiua-11052	77	39	of	of	ADP
aiua-11052	77	40	aberrations	aberration	NOUN
aiua-11052	77	41	on	on	ADP
aiua-11052	77	42	the	the	DET
aiua-11052	77	43	psa	psa	NOUN
aiua-11052	77	44	promoter	promoter	NOUN
aiua-11052	77	45	or	or	CCONJ
aiua-11052	77	46	key	key	ADJ
aiua-11052	77	47	regulators	regulator	NOUN
aiua-11052	77	48	of	of	ADP
aiua-11052	77	49	psa	psa	NOUN
aiua-11052	77	50	production	production	NOUN
aiua-11052	77	51	and	and	CCONJ
aiua-11052	77	52	secretion	secretion	NOUN
aiua-11052	77	53	.	.	PUNCT
aiua-11052	78	1	the	the	DET
aiua-11052	78	2	results	result	NOUN
aiua-11052	78	3	of	of	ADP
aiua-11052	78	4	this	this	DET
aiua-11052	78	5	study	study	NOUN
aiua-11052	78	6	are	be	AUX
aiua-11052	78	7	consistent	consistent	ADJ
aiua-11052	78	8	with	with	ADP
aiua-11052	78	9	rescigno	rescigno	NOUN
aiua-11052	79	1	et	et	PROPN
aiua-11052	79	2	al	al	PROPN
aiua-11052	79	3	.	.	PROPN
aiua-11052	79	4	study	study	PROPN
aiua-11052	79	5	(	(	PUNCT
aiua-11052	79	6	12	12	NUM
aiua-11052	79	7	)	)	PUNCT
aiua-11052	79	8	in	in	ADP
aiua-11052	79	9	which	which	PRON
aiua-11052	79	10	a	a	DET
aiua-11052	79	11	psa	psa	NOUN
aiua-11052	79	12	response	response	NOUN
aiua-11052	79	13	>	>	X
aiua-11052	79	14	30	30	NUM
aiua-11052	79	15	%	%	NOUN
aiua-11052	79	16	was	be	AUX
aiua-11052	79	17	a	a	DET
aiua-11052	79	18	predictor	predictor	NOUN
aiua-11052	79	19	of	of	ADP
aiua-11052	79	20	os	os	NOUN
aiua-11052	79	21	at	at	ADP
aiua-11052	79	22	four	four	NUM
aiua-11052	79	23	weeks	week	NOUN
aiua-11052	79	24	.	.	PUNCT
aiua-11052	80	1	additionally	additionally	ADV
aiua-11052	80	2	,	,	PUNCT
aiua-11052	80	3	these	these	DET
aiua-11052	80	4	results	result	NOUN
aiua-11052	80	5	reported	report	VERB
aiua-11052	80	6	a	a	DET
aiua-11052	80	7	psa	psa	NOUN
aiua-11052	80	8	response	response	NOUN
aiua-11052	80	9	>	>	X
aiua-11052	80	10	30	30	NUM
aiua-11052	80	11	%	%	NOUN
aiua-11052	80	12	and	and	CCONJ
aiua-11052	80	13	>	>	X
aiua-11052	80	14	50	50	NUM
aiua-11052	80	15	%	%	NOUN
aiua-11052	80	16	as	as	ADP
aiua-11052	80	17	statistically	statistically	ADV
aiua-11052	80	18	significant	significant	ADJ
aiua-11052	80	19	for	for	ADP
aiua-11052	80	20	os	os	NOUN
aiua-11052	80	21	at	at	ADP
aiua-11052	80	22	60	60	NUM
aiua-11052	80	23	and	and	CCONJ
aiua-11052	80	24	90	90	NUM
aiua-11052	80	25	days	day	NOUN
aiua-11052	80	26	which	which	PRON
aiua-11052	80	27	suggests	suggest	VERB
aiua-11052	80	28	that	that	SCONJ
aiua-11052	80	29	early	early	ADJ
aiua-11052	80	30	decline	decline	NOUN
aiua-11052	80	31	of	of	ADP
aiua-11052	80	32	this	this	DET
aiua-11052	80	33	biomarker	biomarker	NOUN
aiua-11052	80	34	could	could	AUX
aiua-11052	80	35	be	be	AUX
aiua-11052	80	36	used	use	VERB
aiua-11052	80	37	as	as	ADP
aiua-11052	80	38	a	a	DET
aiua-11052	80	39	clinical	clinical	ADJ
aiua-11052	80	40	tool	tool	NOUN
aiua-11052	80	41	to	to	PART
aiua-11052	80	42	monitor	monitor	VERB
aiua-11052	80	43	treatment	treatment	NOUN
aiua-11052	80	44	response	response	NOUN
aiua-11052	80	45	and	and	CCONJ
aiua-11052	80	46	as	as	ADP
aiua-11052	80	47	a	a	DET
aiua-11052	80	48	prognostic	prognostic	ADJ
aiua-11052	80	49	marker	marker	NOUN
aiua-11052	80	50	for	for	ADP
aiua-11052	80	51	these	these	DET
aiua-11052	80	52	patients	patient	NOUN
aiua-11052	80	53	.	.	PUNCT
aiua-11052	81	1	furthermore	furthermore	ADV
aiua-11052	81	2	,	,	PUNCT
aiua-11052	81	3	it	it	PRON
aiua-11052	81	4	demonstrates	demonstrate	VERB
aiua-11052	81	5	the	the	DET
aiua-11052	81	6	potential	potential	ADJ
aiua-11052	81	7	role	role	NOUN
aiua-11052	81	8	of	of	ADP
aiua-11052	81	9	early	early	ADJ
aiua-11052	81	10	psa	psa	NOUN
aiua-11052	81	11	decline	decline	NOUN
aiua-11052	81	12	as	as	ADP
aiua-11052	81	13	a	a	DET
aiua-11052	81	14	cost	cost	NOUN
aiua-11052	81	15	-	-	PUNCT
aiua-11052	81	16	effective	effective	ADJ
aiua-11052	81	17	tool	tool	NOUN
aiua-11052	81	18	to	to	PART
aiua-11052	81	19	monitor	monitor	VERB
aiua-11052	81	20	mcrpc	mcrpc	NOUN
aiua-11052	81	21	patients	patient	NOUN
aiua-11052	81	22	and	and	CCONJ
aiua-11052	81	23	identify	identify	VERB
aiua-11052	81	24	which	which	PRON
aiua-11052	81	25	patients	patient	NOUN
aiua-11052	81	26	will	will	AUX
aiua-11052	81	27	benefit	benefit	VERB
aiua-11052	81	28	the	the	DET
aiua-11052	81	29	most	most	ADJ
aiua-11052	81	30	from	from	ADP
aiua-11052	81	31	this	this	DET
aiua-11052	81	32	therapy	therapy	NOUN
aiua-11052	81	33	.	.	PUNCT
aiua-11052	82	1	some	some	DET
aiua-11052	82	2	limitations	limitation	NOUN
aiua-11052	82	3	of	of	ADP
aiua-11052	82	4	this	this	DET
aiua-11052	82	5	study	study	NOUN
aiua-11052	82	6	should	should	AUX
aiua-11052	82	7	be	be	AUX
aiua-11052	82	8	noted	note	VERB
aiua-11052	82	9	regarding	regard	VERB
aiua-11052	82	10	it	it	PRON
aiua-11052	82	11	’s	’	VERB
aiua-11052	82	12	retrospective	retrospective	ADJ
aiua-11052	82	13	nature	nature	NOUN
aiua-11052	82	14	and	and	CCONJ
aiua-11052	82	15	a	a	DET
aiua-11052	82	16	relatively	relatively	ADV
aiua-11052	82	17	small	small	ADJ
aiua-11052	82	18	sample	sample	NOUN
aiua-11052	82	19	size	size	NOUN
aiua-11052	82	20	.	.	PUNCT
aiua-11052	83	1	conclusions	conclusion	NOUN
aiua-11052	83	2	abiraterone	abiraterone	NOUN
aiua-11052	83	3	acetate	acetate	NOUN
aiua-11052	83	4	is	be	AUX
aiua-11052	83	5	a	a	DET
aiua-11052	83	6	drug	drug	NOUN
aiua-11052	83	7	of	of	ADP
aiua-11052	83	8	choice	choice	NOUN
aiua-11052	83	9	for	for	ADP
aiua-11052	83	10	crpc	crpc	ADJ
aiua-11052	83	11	and	and	CCONJ
aiua-11052	83	12	also	also	ADV
aiua-11052	83	13	for	for	ADP
aiua-11052	83	14	those	those	PRON
aiua-11052	83	15	who	who	PRON
aiua-11052	83	16	had	have	AUX
aiua-11052	83	17	previously	previously	ADV
aiua-11052	83	18	received	receive	VERB
aiua-11052	83	19	one	one	NUM
aiua-11052	83	20	or	or	CCONJ
aiua-11052	83	21	two	two	NUM
aiua-11052	83	22	chemotherapy	chemotherapy	NOUN
aiua-11052	83	23	regimens	regimen	NOUN
aiua-11052	83	24	.	.	PUNCT
aiua-11052	84	1	this	this	DET
aiua-11052	84	2	data	data	NOUN
aiua-11052	84	3	suggests	suggest	VERB
aiua-11052	84	4	that	that	SCONJ
aiua-11052	84	5	clinicians	clinician	NOUN
aiua-11052	84	6	could	could	AUX
aiua-11052	84	7	utilize	utilize	VERB
aiua-11052	84	8	early	early	ADJ
aiua-11052	84	9	psa	psa	NOUN
aiua-11052	84	10	response	response	NOUN
aiua-11052	84	11	as	as	ADP
aiua-11052	84	12	a	a	DET
aiua-11052	84	13	predictor	predictor	NOUN
aiua-11052	84	14	of	of	ADP
aiua-11052	84	15	subsequent	subsequent	ADJ
aiua-11052	84	16	events	event	NOUN
aiua-11052	84	17	after	after	ADP
aiua-11052	84	18	aa	aa	PROPN
aiua-11052	84	19	therapy	therapy	NOUN
aiua-11052	84	20	.	.	PUNCT
aiua-11052	85	1	it	it	PRON
aiua-11052	85	2	supports	support	VERB
aiua-11052	85	3	a	a	DET
aiua-11052	85	4	meaningful	meaningful	ADJ
aiua-11052	85	5	and	and	CCONJ
aiua-11052	85	6	stronger	strong	ADJ
aiua-11052	85	7	clinical	clinical	ADJ
aiua-11052	85	8	benefit	benefit	NOUN
aiua-11052	85	9	of	of	ADP
aiua-11052	85	10	early	early	ADJ
aiua-11052	85	11	psa	psa	NOUN
aiua-11052	85	12	response	response	NOUN
aiua-11052	85	13	as	as	ADP
aiua-11052	85	14	a	a	DET
aiua-11052	85	15	prognostic	prognostic	ADJ
aiua-11052	85	16	factor	factor	NOUN
aiua-11052	85	17	.	.	PUNCT
aiua-11052	86	1	the	the	DET
aiua-11052	86	2	results	result	NOUN
aiua-11052	86	3	of	of	ADP
aiua-11052	86	4	this	this	DET
aiua-11052	86	5	study	study	NOUN
aiua-11052	86	6	showed	show	VERB
aiua-11052	86	7	that	that	SCONJ
aiua-11052	86	8	aa	aa	PROPN
aiua-11052	86	9	significantly	significantly	ADV
aiua-11052	86	10	lowered	lower	VERB
aiua-11052	86	11	the	the	DET
aiua-11052	86	12	psa	psa	NOUN
aiua-11052	86	13	values	value	NOUN
aiua-11052	86	14	and	and	CCONJ
aiua-11052	86	15	prolonged	prolong	VERB
aiua-11052	86	16	overall	overall	ADJ
aiua-11052	86	17	survival	survival	NOUN
aiua-11052	86	18	in	in	ADP
aiua-11052	86	19	metastatic	metastatic	ADJ
aiua-11052	86	20	castration	castration	NOUN
aiua-11052	86	21	resistant	resistant	ADJ
aiua-11052	86	22	prostate	prostate	NOUN
aiua-11052	86	23	cancer	cancer	NOUN
aiua-11052	86	24	patients	patient	NOUN
aiua-11052	86	25	who	who	PRON
aiua-11052	86	26	had	have	AUX
aiua-11052	86	27	progressed	progress	VERB
aiua-11052	86	28	after	after	ADP
aiua-11052	86	29	first	first	ADJ
aiua-11052	86	30	-	-	PUNCT
aiua-11052	86	31	line	line	NOUN
aiua-11052	86	32	or	or	CCONJ
aiua-11052	86	33	second	second	ADJ
aiua-11052	86	34	-	-	PUNCT
aiua-11052	86	35	line	line	NOUN
aiua-11052	86	36	treatment	treatment	NOUN
aiua-11052	86	37	.	.	PUNCT
aiua-11052	87	1	early	early	ADJ
aiua-11052	87	2	psa	psa	NOUN
aiua-11052	87	3	response	response	NOUN
aiua-11052	87	4	rate	rate	NOUN
aiua-11052	87	5	can	can	AUX
aiua-11052	87	6	provide	provide	VERB
aiua-11052	87	7	clinically	clinically	ADV
aiua-11052	87	8	meaningful	meaningful	ADJ
aiua-11052	87	9	information	information	NOUN
aiua-11052	87	10	and	and	CCONJ
aiua-11052	87	11	can	can	AUX
aiua-11052	87	12	be	be	AUX
aiua-11052	87	13	considered	consider	VERB
aiua-11052	87	14	a	a	DET
aiua-11052	87	15	surrogate	surrogate	NOUN
aiua-11052	87	16	of	of	ADP
aiua-11052	87	17	longer	long	ADJ
aiua-11052	87	18	os	os	NOUN
aiua-11052	87	19	.	.	PUNCT
aiua-11052	88	1	a	a	DET
aiua-11052	88	2	>	>	SYM
aiua-11052	88	3	30	30	NUM
aiua-11052	88	4	%	%	NOUN
aiua-11052	88	5	or	or	CCONJ
aiua-11052	88	6	>	>	SYM
aiua-11052	88	7	50	50	NUM
aiua-11052	88	8	%	%	NOUN
aiua-11052	88	9	prostate	prostate	NOUN
aiua-11052	88	10	-	-	PUNCT
aiua-11052	88	11	specific	specific	ADJ
aiua-11052	88	12	antigen	antigen	NOUN
aiua-11052	88	13	decline	decline	NOUN
aiua-11052	88	14	at	at	ADP
aiua-11052	88	15	60	60	NUM
aiua-11052	88	16	and	and	CCONJ
aiua-11052	88	17	90	90	NUM
aiua-11052	88	18	days	day	NOUN
aiua-11052	88	19	provide	provide	VERB
aiua-11052	88	20	an	an	DET
aiua-11052	88	21	important	important	ADJ
aiua-11052	88	22	clinical	clinical	ADJ
aiua-11052	88	23	tool	tool	NOUN
aiua-11052	88	24	to	to	PART
aiua-11052	88	25	predict	predict	VERB
aiua-11052	88	26	subsequent	subsequent	ADJ
aiua-11052	88	27	events	event	NOUN
aiua-11052	88	28	in	in	ADP
aiua-11052	88	29	mcrpc	mcrpc	NOUN
aiua-11052	88	30	patients	patient	NOUN
aiua-11052	88	31	treated	treat	VERB
aiua-11052	88	32	with	with	ADP
aiua-11052	88	33	abiraterone	abiraterone	NOUN
aiua-11052	88	34	and	and	CCONJ
aiua-11052	88	35	,	,	PUNCT
aiua-11052	88	36	according	accord	VERB
aiua-11052	88	37	to	to	ADP
aiua-11052	88	38	our	our	PRON
aiua-11052	88	39	study	study	NOUN
aiua-11052	88	40	,	,	PUNCT
aiua-11052	88	41	they	they	PRON
aiua-11052	88	42	should	should	AUX
aiua-11052	88	43	be	be	AUX
aiua-11052	88	44	used	use	VERB
aiua-11052	88	45	in	in	ADP
aiua-11052	88	46	clinical	clinical	ADJ
aiua-11052	88	47	practice	practice	NOUN
aiua-11052	88	48	to	to	PART
aiua-11052	88	49	determine	determine	VERB
aiua-11052	88	50	which	which	PRON
aiua-11052	88	51	patients	patient	NOUN
aiua-11052	88	52	will	will	AUX
aiua-11052	88	53	have	have	VERB
aiua-11052	88	54	a	a	DET
aiua-11052	88	55	better	well	ADJ
aiua-11052	88	56	clinical	clinical	ADJ
aiua-11052	88	57	response	response	NOUN
aiua-11052	88	58	and	and	CCONJ
aiua-11052	88	59	as	as	ADP
aiua-11052	88	60	a	a	DET
aiua-11052	88	61	prognostic	prognostic	ADJ
aiua-11052	88	62	marker	marker	NOUN
aiua-11052	88	63	.	.	PUNCT
aiua-11052	89	1	references	reference	NOUN
aiua-11052	89	2	1	1	NUM
aiua-11052	89	3	.	.	PUNCT
aiua-11052	89	4	torre	torre	PROPN
aiua-11052	89	5	la	la	PROPN
aiua-11052	89	6	,	,	PUNCT
aiua-11052	89	7	et	et	PROPN
aiua-11052	89	8	al	al	PROPN
aiua-11052	89	9	.	.	PUNCT
aiua-11052	90	1	global	global	ADJ
aiua-11052	90	2	cancer	cancer	NOUN
aiua-11052	90	3	statistics	statistic	NOUN
aiua-11052	90	4	,	,	PUNCT
aiua-11052	90	5	2012	2012	NUM
aiua-11052	90	6	.	.	PUNCT
aiua-11052	91	1	ca	can	AUX
aiua-11052	91	2	cancer	cancer	PROPN
aiua-11052	91	3	j	j	PROPN
aiua-11052	91	4	clin	clin	PROPN
aiua-11052	91	5	.	.	PUNCT
aiua-11052	92	1	2015	2015	NUM
aiua-11052	92	2	;	;	PUNCT
aiua-11052	92	3	65:87	65:87	NUM
aiua-11052	92	4	-	-	SYM
aiua-11052	92	5	108	108	NUM
aiua-11052	92	6	.	.	PUNCT
aiua-11052	93	1	figure	figure	NOUN
aiua-11052	93	2	6	6	NUM
aiua-11052	93	3	.	.	PUNCT
aiua-11052	94	1	docetaxel	docetaxel	PROPN
aiua-11052	94	2	pre	pre	NOUN
aiua-11052	95	1	-	-	NOUN
aiua-11052	96	1	treatment	treatment	NOUN
aiua-11052	96	2	.	.	PUNCT
aiua-11052	97	1	log	log	PROPN
aiua-11052	97	2	rank	rank	PROPN
aiua-11052	97	3	0.024	0.024	NUM
aiua-11052	97	4	,	,	PUNCT
aiua-11052	97	5	p	p	X
aiua-11052	97	6	=	=	NOUN
aiua-11052	97	7	0.878	0.878	NUM
aiua-11052	97	8	.	.	PUNCT
aiua-11052	98	1	figure	figure	NOUN
aiua-11052	98	2	5	5	NUM
aiua-11052	98	3	.	.	PUNCT
aiua-11052	99	1	roc	roc	PROPN
aiua-11052	99	2	curve	curve	PROPN
aiua-11052	99	3	.	.	PUNCT
aiua-11052	100	1	archivio	archivio	NOUN
aiua-11052	100	2	italiano	italiano	PROPN
aiua-11052	100	3	di	di	PROPN
aiua-11052	100	4	urologia	urologia	PROPN
aiua-11052	100	5	e	e	PROPN
aiua-11052	100	6	andrologia	andrologia	NOUN
aiua-11052	100	7	2023	2023	NUM
aiua-11052	100	8	;	;	PUNCT
aiua-11052	100	9	95	95	NUM
aiua-11052	100	10	,	,	PUNCT
aiua-11052	100	11	1	1	NUM
aiua-11052	100	12	a.	a.	NOUN
aiua-11052	100	13	mendonça	mendonça	PROPN
aiua-11052	100	14	macedo	macedo	PROPN
aiua-11052	100	15	,	,	PUNCT
aiua-11052	100	16	r.	r.	PROPN
aiua-11052	100	17	gameiro	gameiro	PROPN
aiua-11052	100	18	marques	marques	PROPN
aiua-11052	100	19	,	,	PUNCT
aiua-11052	100	20	m.	m.	PROPN
aiua-11052	100	21	cunha	cunha	NOUN
aiua-11052	100	22	andré	andré	PROPN
aiua-11052	100	23	,	,	PUNCT
aiua-11052	100	24	n.	n.	PROPN
aiua-11052	100	25	silva	silva	PROPN
aiua-11052	100	26	figueira	figueira	PROPN
aiua-11052	100	27	,	,	PUNCT
aiua-11052	100	28	m.	m.	NOUN
aiua-11052	100	29	leal	leal	PROPN
aiua-11052	100	30	carvalho	carvalho	PROPN
aiua-11052	100	31	2	2	NUM
aiua-11052	100	32	.	.	PUNCT
aiua-11052	100	33	sartor	sartor	PROPN
aiua-11052	100	34	o	o	PROPN
aiua-11052	100	35	,	,	PUNCT
aiua-11052	100	36	de	de	X
aiua-11052	100	37	bono	bono	X
aiua-11052	100	38	js	js	PROPN
aiua-11052	100	39	.	.	PUNCT
aiua-11052	101	1	metastatic	metastatic	ADJ
aiua-11052	101	2	prostate	prostate	NOUN
aiua-11052	101	3	cancer	cancer	NOUN
aiua-11052	101	4	.	.	PUNCT
aiua-11052	102	1	n	n	PROPN
aiua-11052	102	2	engl	engl	PROPN
aiua-11052	102	3	j	j	PROPN
aiua-11052	102	4	med	med	PROPN
aiua-11052	102	5	.	.	PROPN
aiua-11052	102	6	2018	2018	NUM
aiua-11052	102	7	;	;	PUNCT
aiua-11052	103	1	378:645	378:645	VERB
aiua-11052	103	2	-	-	SYM
aiua-11052	103	3	657	657	NUM
aiua-11052	103	4	.	.	PUNCT
aiua-11052	104	1	3	3	X
aiua-11052	104	2	.	.	X
aiua-11052	104	3	ryan	ryan	PROPN
aiua-11052	104	4	cj	cj	PROPN
aiua-11052	104	5	,	,	PUNCT
aiua-11052	104	6	smith	smith	PROPN
aiua-11052	104	7	mr	mr	PROPN
aiua-11052	104	8	,	,	PUNCT
aiua-11052	104	9	de	de	X
aiua-11052	104	10	bono	bono	X
aiua-11052	104	11	js	js	PROPN
aiua-11052	104	12	,	,	PUNCT
aiua-11052	104	13	et	et	PROPN
aiua-11052	104	14	al	al	PROPN
aiua-11052	104	15	.	.	PUNCT
aiua-11052	104	16	abiraterone	abiraterone	NOUN
aiua-11052	104	17	in	in	ADP
aiua-11052	104	18	metastatic	metastatic	ADJ
aiua-11052	104	19	prostate	prostate	NOUN
aiua-11052	104	20	cancer	cancer	NOUN
aiua-11052	104	21	without	without	ADP
aiua-11052	104	22	previous	previous	ADJ
aiua-11052	104	23	chemotherapy	chemotherapy	NOUN
aiua-11052	104	24	.	.	PUNCT
aiua-11052	105	1	n	n	PROPN
aiua-11052	105	2	engl	engl	PROPN
aiua-11052	105	3	j	j	PROPN
aiua-11052	105	4	med	med	PROPN
aiua-11052	105	5	.	.	PUNCT
aiua-11052	106	1	2013	2013	NUM
aiua-11052	106	2	;	;	PUNCT
aiua-11052	106	3	368:138	368:138	NUM
aiua-11052	106	4	-	-	SYM
aiua-11052	106	5	148	148	NUM
aiua-11052	106	6	.	.	PUNCT
aiua-11052	107	1	4	4	NUM
aiua-11052	107	2	.	.	X
aiua-11052	107	3	beer	beer	PROPN
aiua-11052	107	4	tm	tm	PROPN
aiua-11052	107	5	,	,	PUNCT
aiua-11052	107	6	armstrong	armstrong	PROPN
aiua-11052	107	7	aj	aj	PROPN
aiua-11052	107	8	,	,	PUNCT
aiua-11052	107	9	rathkopf	rathkopf	VERB
aiua-11052	107	10	de	de	PROPN
aiua-11052	107	11	,	,	PUNCT
aiua-11052	107	12	et	et	PROPN
aiua-11052	107	13	al	al	PROPN
aiua-11052	107	14	.	.	PROPN
aiua-11052	108	1	enzalutamide	enzalutamide	PROPN
aiua-11052	108	2	in	in	ADP
aiua-11052	108	3	metastatic	metastatic	ADJ
aiua-11052	108	4	prostate	prostate	NOUN
aiua-11052	108	5	cancer	cancer	NOUN
aiua-11052	108	6	before	before	ADP
aiua-11052	108	7	chemotherapy	chemotherapy	NOUN
aiua-11052	108	8	.	.	PUNCT
aiua-11052	109	1	n	n	PROPN
aiua-11052	109	2	engl	engl	PROPN
aiua-11052	109	3	j	j	PROPN
aiua-11052	109	4	med	med	PROPN
aiua-11052	109	5	.	.	PUNCT
aiua-11052	109	6	2014	2014	NUM
aiua-11052	109	7	;	;	PUNCT
aiua-11052	109	8	371:424	371:424	NUM
aiua-11052	109	9	-	-	SYM
aiua-11052	109	10	33	33	NUM
aiua-11052	109	11	.	.	PUNCT
aiua-11052	110	1	5	5	NUM
aiua-11052	110	2	.	.	X
aiua-11052	110	3	fizazi	fizazi	PROPN
aiua-11052	110	4	k	k	PROPN
aiua-11052	110	5	,	,	PUNCT
aiua-11052	110	6	scher	scher	PROPN
aiua-11052	110	7	hl	hl	PROPN
aiua-11052	110	8	,	,	PUNCT
aiua-11052	110	9	molina	molina	PROPN
aiua-11052	110	10	a	a	PROPN
aiua-11052	110	11	et	et	PROPN
aiua-11052	110	12	al	al	PROPN
aiua-11052	110	13	.	.	PUNCT
aiua-11052	110	14	abiraterone	abiraterone	NOUN
aiua-11052	110	15	acetate	acetate	NOUN
aiua-11052	110	16	for	for	ADP
aiua-11052	110	17	treatment	treatment	NOUN
aiua-11052	110	18	of	of	ADP
aiua-11052	110	19	metastatic	metastatic	ADJ
aiua-11052	110	20	castration	castration	NOUN
aiua-11052	110	21	-	-	PUNCT
aiua-11052	110	22	resistant	resistant	ADJ
aiua-11052	110	23	prostate	prostate	NOUN
aiua-11052	110	24	cancer	cancer	NOUN
aiua-11052	110	25	:	:	PUNCT
aiua-11052	110	26	final	final	ADJ
aiua-11052	110	27	overall	overall	ADJ
aiua-11052	110	28	survival	survival	NOUN
aiua-11052	110	29	analysis	analysis	NOUN
aiua-11052	110	30	of	of	ADP
aiua-11052	110	31	the	the	DET
aiua-11052	110	32	cou	cou	PROPN
aiua-11052	110	33	-	-	PUNCT
aiua-11052	110	34	aa	aa	PROPN
aiua-11052	110	35	301	301	NUM
aiua-11052	110	36	randomised	randomise	VERB
aiua-11052	110	37	,	,	PUNCT
aiua-11052	110	38	double	double	ADJ
aiua-11052	110	39	-	-	PUNCT
aiua-11052	110	40	blind	blind	ADJ
aiua-11052	110	41	,	,	PUNCT
aiua-11052	110	42	placebo	placebo	NOUN
aiua-11052	110	43	-	-	PUNCT
aiua-11052	110	44	controlled	control	VERB
aiua-11052	110	45	phase	phase	NOUN
aiua-11052	110	46	iii	iii	NUM
aiua-11052	110	47	study	study	NOUN
aiua-11052	110	48	.	.	PUNCT
aiua-11052	111	1	lancet	lancet	PROPN
aiua-11052	111	2	oncol	oncol	PROPN
aiua-11052	111	3	.	.	PUNCT
aiua-11052	112	1	2012	2012	NUM
aiua-11052	112	2	;	;	PUNCT
aiua-11052	112	3	13:983	13:983	NUM
aiua-11052	112	4	-	-	SYM
aiua-11052	112	5	925	925	NUM
aiua-11052	112	6	.	.	NOUN
aiua-11052	113	1	6	6	NUM
aiua-11052	113	2	.	.	X
aiua-11052	113	3	schlack	schlack	PROPN
aiua-11052	113	4	k	k	PROPN
aiua-11052	113	5	,	,	PUNCT
aiua-11052	113	6	krabbe	krabbe	NOUN
aiua-11052	113	7	lm	lm	PROPN
aiua-11052	113	8	,	,	PUNCT
aiua-11052	113	9	fobker	fobker	NOUN
aiua-11052	113	10	m	m	PROPN
aiua-11052	113	11	,	,	PUNCT
aiua-11052	113	12	et	et	PROPN
aiua-11052	113	13	al	al	PROPN
aiua-11052	113	14	.	.	PUNCT
aiua-11052	114	1	early	early	ADJ
aiua-11052	114	2	prediction	prediction	NOUN
aiua-11052	114	3	of	of	ADP
aiua-11052	114	4	therapy	therapy	NOUN
aiua-11052	114	5	response	response	NOUN
aiua-11052	114	6	to	to	ADP
aiua-11052	114	7	abiraterone	abiraterone	NOUN
aiua-11052	114	8	acetate	acetate	NOUN
aiua-11052	114	9	using	use	VERB
aiua-11052	114	10	psa	psa	NOUN
aiua-11052	114	11	subforms	subform	NOUN
aiua-11052	114	12	in	in	ADP
aiua-11052	114	13	patients	patient	NOUN
aiua-11052	114	14	with	with	ADP
aiua-11052	114	15	castration	castration	NOUN
aiua-11052	114	16	resistant	resistant	ADJ
aiua-11052	114	17	prostate	prostate	NOUN
aiua-11052	114	18	cancer	cancer	NOUN
aiua-11052	114	19	.	.	PUNCT
aiua-11052	115	1	int	int	PROPN
aiua-11052	115	2	j	j	PROPN
aiua-11052	115	3	mol	mol	ADP
aiua-11052	115	4	sci	sci	PROPN
aiua-11052	115	5	.	.	PROPN
aiua-11052	115	6	2016	2016	NUM
aiua-11052	115	7	;	;	PUNCT
aiua-11052	115	8	17:1520	17:1520	X
aiua-11052	115	9	.	.	X
aiua-11052	116	1	7	7	X
aiua-11052	116	2	.	.	PUNCT
aiua-11052	116	3	facchini	facchini	PROPN
aiua-11052	116	4	halabi	halabi	PROPN
aiua-11052	116	5	a	a	PROPN
aiua-11052	116	6	,	,	PUNCT
aiua-11052	116	7	armstrong	armstrong	PROPN
aiua-11052	116	8	aj	aj	PROPN
aiua-11052	116	9	,	,	PUNCT
aiua-11052	116	10	sartor	sartor	PROPN
aiua-11052	116	11	o	o	PROPN
aiua-11052	116	12	,	,	PUNCT
aiua-11052	116	13	et	et	PROPN
aiua-11052	116	14	al	al	PROPN
aiua-11052	116	15	.	.	PUNCT
aiua-11052	116	16	prostate	prostate	NOUN
aiua-11052	116	17	-	-	PUNCT
aiua-11052	116	18	specific	specific	ADJ
aiua-11052	116	19	antigen	antigen	ADJ
aiua-11052	116	20	changes	change	NOUN
aiua-11052	116	21	as	as	ADP
aiua-11052	116	22	surrogate	surrogate	ADJ
aiua-11052	116	23	for	for	ADP
aiua-11052	116	24	overall	overall	ADJ
aiua-11052	116	25	survival	survival	NOUN
aiua-11052	116	26	in	in	ADP
aiua-11052	116	27	men	man	NOUN
aiua-11052	116	28	with	with	ADP
aiua-11052	116	29	metastatic	metastatic	ADJ
aiua-11052	116	30	castration	castration	NOUN
aiua-11052	116	31	-	-	PUNCT
aiua-11052	116	32	resistant	resistant	ADJ
aiua-11052	116	33	prostate	prostate	NOUN
aiua-11052	116	34	cancer	cancer	NOUN
aiua-11052	116	35	treated	treat	VERB
aiua-11052	116	36	with	with	ADP
aiua-11052	116	37	secondline	secondline	ADJ
aiua-11052	116	38	chemotherapy	chemotherapy	NOUN
aiua-11052	116	39	.	.	PUNCT
aiua-11052	117	1	j	j	PROPN
aiua-11052	117	2	clin	clin	PROPN
aiua-11052	117	3	oncol	oncol	PROPN
aiua-11052	117	4	.	.	PUNCT
aiua-11052	118	1	2013	2013	NUM
aiua-11052	118	2	;	;	PUNCT
aiua-11052	118	3	31:3944	31:3944	NUM
aiua-11052	118	4	-	-	SYM
aiua-11052	118	5	3950	3950	NUM
aiua-11052	118	6	.	.	PUNCT
aiua-11052	119	1	8	8	NUM
aiua-11052	119	2	.	.	X
aiua-11052	119	3	verzoni	verzoni	PROPN
aiua-11052	119	4	e	e	PROPN
aiua-11052	119	5	,	,	PUNCT
aiua-11052	119	6	de	de	PROPN
aiua-11052	119	7	giorgi	giorgi	PROPN
aiua-11052	119	8	u	u	PROPN
aiua-11052	119	9	,	,	PUNCT
aiua-11052	119	10	derosa	derosa	PROPN
aiua-11052	119	11	l	l	PROPN
aiua-11052	119	12	,	,	PUNCT
aiua-11052	119	13	et	et	PROPN
aiua-11052	119	14	al	al	PROPN
aiua-11052	119	15	.	.	PUNCT
aiua-11052	119	16	predictors	predictor	NOUN
aiua-11052	119	17	of	of	ADP
aiua-11052	119	18	long	long	ADJ
aiua-11052	119	19	-	-	PUNCT
aiua-11052	119	20	term	term	NOUN
aiua-11052	119	21	response	response	NOUN
aiua-11052	119	22	to	to	ADP
aiua-11052	119	23	abiraterone	abiraterone	NOUN
aiua-11052	119	24	in	in	ADP
aiua-11052	119	25	patients	patient	NOUN
aiua-11052	119	26	with	with	ADP
aiua-11052	119	27	metastatic	metastatic	ADJ
aiua-11052	119	28	castration	castration	NOUN
aiua-11052	119	29	-	-	PUNCT
aiua-11052	119	30	resistant	resistant	ADJ
aiua-11052	119	31	prostate	prostate	NOUN
aiua-11052	119	32	cancer	cancer	NOUN
aiua-11052	119	33	:	:	PUNCT
aiua-11052	119	34	a	a	DET
aiua-11052	119	35	retrospective	retrospective	ADJ
aiua-11052	119	36	cohort	cohort	NOUN
aiua-11052	119	37	study	study	NOUN
aiua-11052	119	38	.	.	PUNCT
aiua-11052	120	1	oncotarget	oncotarget	NOUN
aiua-11052	120	2	.	.	PUNCT
aiua-11052	121	1	2016	2016	NUM
aiua-11052	121	2	;	;	PUNCT
aiua-11052	121	3	7:40085	7:40085	NUM
aiua-11052	121	4	-	-	SYM
aiua-11052	121	5	40094	40094	NUM
aiua-11052	121	6	.	.	PUNCT
aiua-11052	122	1	9	9	X
aiua-11052	122	2	.	.	X
aiua-11052	122	3	izumi	izumi	PROPN
aiua-11052	122	4	k	k	PROPN
aiua-11052	122	5	,	,	PUNCT
aiua-11052	122	6	mizokami	mizokami	PROPN
aiua-11052	122	7	a	a	PRON
aiua-11052	122	8	,	,	PUNCT
aiua-11052	122	9	namiki	namiki	PROPN
aiua-11052	122	10	m	m	PROPN
aiua-11052	122	11	,	,	PUNCT
aiua-11052	122	12	et	et	PROPN
aiua-11052	122	13	al	al	PROPN
aiua-11052	122	14	.	.	PROPN
aiua-11052	122	15	enzalutamide	enzalutamide	PROPN
aiua-11052	122	16	versus	versus	ADP
aiua-11052	122	17	abiraterone	abiraterone	NOUN
aiua-11052	122	18	as	as	ADP
aiua-11052	122	19	a	a	DET
aiua-11052	122	20	first	first	ADJ
aiua-11052	122	21	-	-	PUNCT
aiua-11052	122	22	line	line	NOUN
aiua-11052	122	23	endocrine	endocrine	NOUN
aiua-11052	122	24	therapy	therapy	NOUN
aiua-11052	122	25	for	for	ADP
aiua-11052	122	26	castration	castration	NOUN
aiua-11052	122	27	-	-	PUNCT
aiua-11052	122	28	resistant	resistant	ADJ
aiua-11052	122	29	prostate	prostate	NOUN
aiua-11052	122	30	cancer	cancer	NOUN
aiua-11052	122	31	(	(	PUNCT
aiua-11052	122	32	enable	enable	VERB
aiua-11052	122	33	study	study	NOUN
aiua-11052	122	34	for	for	ADP
aiua-11052	122	35	pca	pca	PROPN
aiua-11052	122	36	):	):	PUNCT
aiua-11052	122	37	a	a	DET
aiua-11052	122	38	study	study	NOUN
aiua-11052	122	39	protocol	protocol	NOUN
aiua-11052	122	40	for	for	ADP
aiua-11052	122	41	a	a	DET
aiua-11052	122	42	multicenter	multicenter	NOUN
aiua-11052	122	43	randomized	randomize	VERB
aiua-11052	122	44	phase	phase	NOUN
aiua-11052	122	45	iii	iii	NOUN
aiua-11052	122	46	trial	trial	NOUN
aiua-11052	122	47	.	.	PUNCT
aiua-11052	123	1	bmc	bmc	NOUN
aiua-11052	123	2	cancer	cancer	NOUN
aiua-11052	123	3	.	.	PUNCT
aiua-11052	124	1	2017	2017	NUM
aiua-11052	124	2	;	;	PUNCT
aiua-11052	124	3	17:677	17:677	NUM
aiua-11052	124	4	.	.	PUNCT
aiua-11052	125	1	10	10	NUM
aiua-11052	125	2	.	.	PUNCT
aiua-11052	125	3	jarimba	jarimba	ADJ
aiua-11052	125	4	rs	rs	PROPN
aiua-11052	125	5	,	,	PUNCT
aiua-11052	125	6	eliseu	eliseu	PROPN
aiua-11052	125	7	mn	mn	PROPN
aiua-11052	125	8	,	,	PUNCT
aiua-11052	125	9	pedroso	pedroso	VERB
aiua-11052	125	10	lima	lima	PROPN
aiua-11052	125	11	j	j	PROPN
aiua-11052	125	12	,	,	PUNCT
aiua-11052	125	13	et	et	PROPN
aiua-11052	126	1	al	al	PROPN
aiua-11052	126	2	.	.	PROPN
aiua-11052	126	3	novel	novel	ADJ
aiua-11052	126	4	hormonal	hormonal	ADJ
aiua-11052	126	5	agents	agent	NOUN
aiua-11052	126	6	for	for	ADP
aiua-11052	126	7	metastatic	metastatic	ADJ
aiua-11052	126	8	castration	castration	NOUN
aiua-11052	126	9	-	-	PUNCT
aiua-11052	126	10	resistant	resistant	ADJ
aiua-11052	126	11	prostate	prostate	NOUN
aiua-11052	126	12	cancer	cancer	NOUN
aiua-11052	126	13	:	:	PUNCT
aiua-11052	126	14	comparing	compare	VERB
aiua-11052	126	15	outcomes	outcome	NOUN
aiua-11052	126	16	.	.	PUNCT
aiua-11052	127	1	a	a	DET
aiua-11052	127	2	single	single	ADJ
aiua-11052	127	3	-	-	PUNCT
aiua-11052	127	4	center	center	NOUN
aiua-11052	127	5	retrospective	retrospective	ADJ
aiua-11052	127	6	study	study	NOUN
aiua-11052	127	7	.	.	PUNCT
aiua-11052	128	1	arch	arch	PROPN
aiua-11052	128	2	ital	ital	PROPN
aiua-11052	128	3	urol	urol	PROPN
aiua-11052	128	4	androl	androl	PROPN
aiua-11052	128	5	.	.	PROPN
aiua-11052	128	6	2021	2021	NUM
aiua-11052	128	7	;	;	PUNCT
aiua-11052	128	8	93:393	93:393	NUM
aiua-11052	128	9	-	-	SYM
aiua-11052	128	10	8	8	NUM
aiua-11052	128	11	.	.	NOUN
aiua-11052	128	12	11	11	NUM
aiua-11052	128	13	.	.	PUNCT
aiua-11052	129	1	gomella	gomella	NOUN
aiua-11052	129	2	lg	lg	PROPN
aiua-11052	129	3	,	,	PUNCT
aiua-11052	129	4	oliver	oliver	PROPN
aiua-11052	129	5	sartor	sartor	PROPN
aiua-11052	129	6	a.	a.	PROPN
aiua-11052	129	7	the	the	DET
aiua-11052	129	8	current	current	ADJ
aiua-11052	129	9	role	role	NOUN
aiua-11052	129	10	and	and	CCONJ
aiua-11052	129	11	limitations	limitation	NOUN
aiua-11052	129	12	of	of	ADP
aiua-11052	129	13	surrogate	surrogate	ADJ
aiua-11052	129	14	endpoints	endpoint	NOUN
aiua-11052	129	15	in	in	ADP
aiua-11052	129	16	advanced	advanced	ADJ
aiua-11052	129	17	prostate	prostate	NOUN
aiua-11052	129	18	cancer	cancer	NOUN
aiua-11052	129	19	.	.	PUNCT
aiua-11052	130	1	urol	urol	PROPN
aiua-11052	130	2	oncol	oncol	PROPN
aiua-11052	130	3	.	.	PUNCT
aiua-11052	131	1	2014	2014	NUM
aiua-11052	131	2	;	;	PUNCT
aiua-11052	131	3	32:28.e1	32:28.e1	NOUN
aiua-11052	131	4	-	-	SYM
aiua-11052	131	5	9	9	NUM
aiua-11052	131	6	.	.	NOUN
aiua-11052	131	7	12	12	NUM
aiua-11052	131	8	.	.	PUNCT
aiua-11052	132	1	rescigno	rescigno	NOUN
aiua-11052	132	2	p	p	X
aiua-11052	132	3	,	,	PUNCT
aiua-11052	132	4	lorente	lorente	NOUN
aiua-11052	132	5	d	d	PROPN
aiua-11052	132	6	,	,	PUNCT
aiua-11052	132	7	bianchini	bianchini	PROPN
aiua-11052	132	8	d	d	PROPN
aiua-11052	132	9	,	,	PUNCT
aiua-11052	132	10	et	et	PROPN
aiua-11052	132	11	al	al	PROPN
aiua-11052	132	12	.	.	PUNCT
aiua-11052	132	13	prostate	prostate	NOUN
aiua-11052	132	14	-	-	PUNCT
aiua-11052	132	15	specific	specific	ADJ
aiua-11052	132	16	antigen	antigen	NOUN
aiua-11052	132	17	decline	decline	NOUN
aiua-11052	132	18	after	after	ADP
aiua-11052	132	19	4	4	NUM
aiua-11052	132	20	weeks	week	NOUN
aiua-11052	132	21	of	of	ADP
aiua-11052	132	22	treatment	treatment	NOUN
aiua-11052	132	23	with	with	ADP
aiua-11052	132	24	abiraterone	abiraterone	NOUN
aiua-11052	132	25	acetate	acetate	NOUN
aiua-11052	132	26	and	and	CCONJ
aiua-11052	132	27	overall	overall	ADJ
aiua-11052	132	28	survival	survival	NOUN
aiua-11052	132	29	in	in	ADP
aiua-11052	132	30	patients	patient	NOUN
aiua-11052	132	31	with	with	ADP
aiua-11052	132	32	metastatic	metastatic	ADJ
aiua-11052	132	33	castration	castration	NOUN
aiua-11052	132	34	-	-	PUNCT
aiua-11052	132	35	resistant	resistant	ADJ
aiua-11052	132	36	prostate	prostate	NOUN
aiua-11052	132	37	cancer	cancer	NOUN
aiua-11052	132	38	.	.	PUNCT
aiua-11052	133	1	eur	eur	PROPN
aiua-11052	133	2	urol	urol	PROPN
aiua-11052	133	3	.	.	PUNCT
aiua-11052	134	1	2016	2016	NUM
aiua-11052	134	2	;	;	PUNCT
aiua-11052	134	3	70:724	70:724	NUM
aiua-11052	134	4	-	-	SYM
aiua-11052	134	5	731	731	NUM
aiua-11052	134	6	.	.	PUNCT
aiua-11052	135	1	correspondence	correspondence	NOUN
aiua-11052	135	2	alexandre	alexandre	PROPN
aiua-11052	135	3	mendonça	mendonça	PROPN
aiua-11052	135	4	macedo	macedo	PROPN
aiua-11052	135	5	,	,	PUNCT
aiua-11052	135	6	md	md	PROPN
aiua-11052	135	7	(	(	PUNCT
aiua-11052	135	8	corresponding	correspond	VERB
aiua-11052	135	9	author	author	NOUN
aiua-11052	135	10	)	)	PUNCT
aiua-11052	135	11	alex.m.macedo89@gmail.com	alex.m.macedo89@gmail.com	VERB
aiua-11052	135	12	hospital	hospital	PROPN
aiua-11052	135	13	garcia	garcia	PROPN
aiua-11052	135	14	de	de	PROPN
aiua-11052	135	15	orta	orta	PROPN
aiua-11052	135	16	,	,	PUNCT
aiua-11052	135	17	epe	epe	PROPN
aiua-11052	135	18	av	av	PROPN
aiua-11052	135	19	.	.	PROPN
aiua-11052	135	20	prof	prof	PROPN
aiua-11052	135	21	.	.	PUNCT
aiua-11052	136	1	torrado	torrado	PROPN
aiua-11052	136	2	da	da	PROPN
aiua-11052	136	3	silva	silva	PROPN
aiua-11052	136	4	,	,	PUNCT
aiua-11052	136	5	2801	2801	NUM
aiua-11052	136	6	-	-	SYM
aiua-11052	136	7	951	951	NUM
aiua-11052	136	8	almada	almada	PROPN
aiua-11052	136	9	,	,	PUNCT
aiua-11052	136	10	portugal	portugal	PROPN
aiua-11052	136	11	margarida	margarida	PROPN
aiua-11052	136	12	cunha	cunha	PROPN
aiua-11052	136	13	andré	andré	PROPN
aiua-11052	136	14	,	,	PUNCT
aiua-11052	136	15	md	md	PROPN
aiua-11052	136	16	margaridamcandre@gmail.com	margaridamcandre@gmail.com	PROPN
aiua-11052	137	1	nuno	nuno	PROPN
aiua-11052	137	2	silva	silva	PROPN
aiua-11052	137	3	figueira	figueira	PROPN
aiua-11052	137	4	,	,	PUNCT
aiua-11052	137	5	md	md	PROPN
aiua-11052	137	6	nunofigueira456@gmail.com	nunofigueira456@gmail.com	PROPN
aiua-11052	138	1	miguel	miguel	PROPN
aiua-11052	138	2	leal	leal	PROPN
aiua-11052	138	3	carvalho	carvalho	PROPN
aiua-11052	138	4	,	,	PUNCT
aiua-11052	138	5	md	md	PROPN
aiua-11052	138	6	uro.miguelcarvalho@gmail.com	uro.miguelcarvalho@gmail.com	PROPN
aiua-11052	138	7	urology	urology	PROPN
aiua-11052	138	8	department	department	PROPN
aiua-11052	138	9	,	,	PUNCT
aiua-11052	138	10	hospital	hospital	NOUN
aiua-11052	138	11	garcia	garcia	PROPN
aiua-11052	138	12	de	de	PROPN
aiua-11052	138	13	orta	orta	PROPN
aiua-11052	138	14	epe	epe	PROPN
aiua-11052	138	15	,	,	PUNCT
aiua-11052	138	16	almada	almada	PROPN
aiua-11052	138	17	(	(	PUNCT
aiua-11052	138	18	portugal	portugal	PROPN
aiua-11052	138	19	)	)	PUNCT
aiua-11052	138	20	rita	rita	PROPN
aiua-11052	138	21	gameiro	gameiro	PROPN
aiua-11052	138	22	marques	marques	PROPN
aiua-11052	138	23	,	,	PUNCT
aiua-11052	138	24	md	md	PROPN
aiua-11052	138	25	ritagameiros@gmail.com	ritagameiros@gmail.com	PROPN
aiua-11052	138	26	oncology	oncology	PROPN
aiua-11052	138	27	department	department	PROPN
aiua-11052	138	28	,	,	PUNCT
aiua-11052	138	29	centro	centro	PROPN
aiua-11052	138	30	hospitalar	hospitalar	PROPN
aiua-11052	138	31	barreiro	barreiro	PROPN
aiua-11052	138	32	montijo	montijo	PROPN
aiua-11052	138	33	,	,	PUNCT
aiua-11052	138	34	barreiro	barreiro	PROPN
aiua-11052	138	35	(	(	PUNCT
aiua-11052	138	36	portugal	portugal	PROPN
aiua-11052	138	37	)	)	PUNCT
aiua-11052	138	38	conflict	conflict	NOUN
aiua-11052	138	39	of	of	ADP
aiua-11052	138	40	interest	interest	NOUN
aiua-11052	138	41	:	:	PUNCT
aiua-11052	138	42	the	the	DET
aiua-11052	138	43	authors	author	NOUN
aiua-11052	138	44	declare	declare	VERB
aiua-11052	138	45	no	no	DET
aiua-11052	138	46	potential	potential	ADJ
aiua-11052	138	47	conflict	conflict	NOUN
aiua-11052	138	48	of	of	ADP
aiua-11052	138	49	interest	interest	NOUN
aiua-11052	138	50	.	.	PUNCT